CUMULATIVE SUPPLEMENT 6

JAN'93-JUN'93

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

1.0
1.1
1.2
1.3
1.4
1.5

2.0
2.1
2.2
2.3

2.4
2.5

2.6
2.7

PAT

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 6

JUNE 1993

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Products Requiring Revised Labeling for Full Approval	v
1.3	Applicant Name Changes	vi
1.4	USP Monograph Title Additions or Changes	vii
1.5	Report of Counts for the Prescription Drug Product List	viii
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	49
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	51
2.4	Orphan Drug Product Designations	52
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	55
2.6	Biopharmaceutic Guidance Availability	56
2.7	ANDA Suitability Petitions	57
	PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
	A. Exclusivity Terms	58
	B. Patent and Exclusivity Lists	59

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 6

JUNE 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ə " symbol to designate their non-marketed status. All products having a " ə " symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AH ROBINS CO (ROBINS)	AH ROBINS CO (ROBINS AH)
ASTRA PHARMACEUTICAL PRODUCTS INC (ASTRA)	ASTRA USA INC (ASTRA)
BAKER CUMMINS PHARMACEUTICALS INC (BAKER CUMMINS)	BAKER NORTON PHARMACEUTICALS INC (BAKER NORTON)
BENEDICT NUCLEAR PHARMACEUTICALS INC (BENEDICT)	NORTH AMERICAN CHEMICAL CORPORATION (NORTH AM CHEM)
BOLAR PHARMACEUTICAL CO INC (BOLAR)	CIRCA PHARMACEUTICALS INC (CIRCA)
CIS US INC (CIS)	CIS US INC (CIS US)
CUTTER BIOLOGICAL DIV MILES LABORATORIES INC (CUTTER)	MILES LABORATORIES INC (MILES LABS)
FUJISAWA PHARMACEUTICAL CO (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)
HERBERT LABORATORIES DIV SMITH KLINE AND FRENCH CO (HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN HERBERT)
LYPHOMED DIV FUJISAWA USA INC (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ROXANE LABORATORIES INC (ROXANE)	ROXANE LABORATORIES INC (ROXANE LABS)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV MCNEILAB (JOHNSON RW)	RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)
SCHIAPPARELLI SEARLE (SCHIAPPARELLI SEARLE)	SCS PHARMACEUTICALS (SCS PHARMS)
SOMERSET PHARMACEUTICALS INC (SOMERSET)	SOMERSET PHARMACEUTICALS INC (SOMERSET PHARMS)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF JUNE 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1992	MAR 1993	JUN 1993	SEP 1993
DRUG PRODUCTS LISTED	9488	9392	9194	
SINGLE SOURCE	2245 (23.7%)	2243 (23.9%)	2119 (23.0%)	
MULTISOURCE	7243 (76.3%)	7149 (76.1%)	7075 (77.0%)	
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6432 (68.5%)	6357 (69.1%)	
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	562 (5.9%)	555 (6.1%)	
EXCEPTIONS[1]	150 (1.6%)	155 (1.7%)	163 (1.8%)	
NEW MOLECULAR ENTITIES APPROVED	--	3	2	
NUMBER OF APPLICANTS	477	484	508	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
ANOQUAN

/AB/	/MALLARD/	/325MG;50MG;40MG/	/N87628/001/ /OCT/01,/1986/
AB	ROBERTS HAUCK	325MG;50MG;40MG	N87628 001 OCT 01, 1986

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
COMPAL

AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
/AA/	/SOLVAY/	/356.4MG;30MG;16MG/	/N88584/001/ /MAR/04,/1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LEMMON		300MG;30MG	N88324 001 DEC 29, 1983
/ACETAMINOPHEN/W/CODEINE/#3/	/LEMMON/	/300MG;30MG/	/N88324/001/ /DEC/29,/1983/

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL
ALLAY

/AA/	/LUCHEM/	/500MG;5MG/	/N89907/001/ /JAN/13,/1989/
AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989

TABLET; ORAL
ANEXSIA

AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001 APR 23, 1987
/AA/	/SKCP/	/500MG;5MG/	/N89160/001/ /APR/23,/1987/

ANEXSIA 7.5/650

AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001 SEP 30, 1987
/AA/	/SKCP/	/650MG;7.5MG/	/N89725/001/ /SEP/30,/1987/

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
/DURADYNE DHC/

/AA/	/FOREST PHARMS/	/500MG;5MG/	/N87809/001/ /MAR/17,/1983/
@ FOREST PHARMS		500MG;5MG	N87809 001 MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/	/LUCHEM/	/500MG;5MG/	/N89696/001/ /APR/21,/1988/
AA	NORTON HN	500MG;5MG	N89696 001 APR 21, 1988

/NORCET/

/AA/	/ABANA/	/500MG;5MG/	/N88871/001/ /MAY/15,/1986/
@ ABANA		500MG;5MG	N88871 001 MAY 15, 1986

/TYCOLET/

/AA/	/JOHNSON/RW/	/500MG;5MG/	/N89385/001/ /AUG/27,/1986/
@ JOHNSON RW		500MG;5MG	N89385 001 AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>DLT>	/AB/	/HALSEY/	/650MG;100MG/	/N72106/001/ /MAY/13,/1988/
>DLT>				
>ADD>	@ HALSEY		650MG;100MG	N72106 001 MAY 13, 1988
>ADD>				

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
/ACETAZOLAMIDE SODIUM/

/AP/	/QUAD/	/EQ 500MG/VIAL/	/N89619/001/ /JAN/13,/1988/
@ QUAD		EQ 500MG/VIAL	N89619 001 JAN 13, 1988

DIAMOX

/AP/	/LEDERLE/	/EQ 500MG/VIAL/	/N09388/001/ /DEC/05,/1990/
LEDERLE		EQ 500MG/VIAL	N09388 001 DEC 05, 1990

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ZOVIRAX
+ BURROUGHS WELLCOME — EQ 1GM BASE/VIAL — N18603 002 JUN 29, 1989
∂ — EQ 250MG BASE/VIAL — N18603 003 AUG 30, 1983

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN COPLEY — EQ 0.083% BASE — N73495 001 MAY 28, 1993

SYRUP; ORAL
ALBUTEROL SULFATE
AA WATSON LABS — EQ 2MG BASE/5ML — N73165 001 APR 29, 1993

TABLET; ORAL
ALBUTEROL SULFATE
> ADD > AB NOVOPHARM — EQ 2MG BASE — N72779 001 JUN 25, 1993
> ADD >
> ADD > AB — EQ 4MG BASE — N72780 001 JUN 25, 1993
> ADD >

TABLET, EXTENDED RELEASE; ORAL
PROVENTIL
/AB//+//SCHERING/ — /EQ 4MG BASE/ — /N19383/001/ /JUL/13,/1987/
BC + SCHERING — EQ 4MG BASE — N19383 001 JUL 13, 1987

VOLMAX
/AB/ /GLAXO/ — /EQ 4MG BASE/ — /N19604/002/ /DEC/23,/1992/
BC GLAXO — EQ 4MG BASE — N19604 002 DEC 23, 1992

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL
/AB/ /BOLAR/ — /100MG/ — /N71382/001/ /JAN/21,/1987/
∂ BOLAR — 100MG — N71382 001 JAN 21, 1987

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
> ADD > AA MIKART — 50MG/5ML — N74028 001 JUN 28, 1993
> ADD >

/TABLET;/ORAL/
/SYMMETREL/
/+//DUPONT/ — /100MG/ — /N18101/001/
∂ DUPONT — 100MG — N18101 001

AMDINOCILLIN

/INJECTABLE;/INJECTION/
/COACTIN/
/ROCHE/ — /250MG/VIAL/ — /N50565/001/ /DEC/21,/1984/
/500MG/VIAL/ — /N50565/002/ /DEC/21,/1984/
/1GM/VIAL/ — /N50565/003/ /DEC/21,/1984/
∂ ROCHE — 250MG/VIAL — N50565 001 DEC 21, 1984
∂ — 500MG/VIAL — N50565 002 DEC 21, 1984
∂ — 1GM/VIAL — N50565 003 DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/
> DLT > /BRISTOL/ — /EQ/5MG/BASE/ML/ — /N50618/002/ /NOV/30,/1987/
> DLT > — /EQ/10MG/BASE/ML/ — /N50618/001/ /NOV/30,/1987/
> DLT >
> DLT >
> DLT >
> ADD > ∂ BRISTOL — EQ 5MG BASE/ML — N50618 002 NOV 30, 1987
> ADD >
> ADD > ∂ — EQ 10MG BASE/ML — N50618 001 NOV 30, 1987
> ADD >

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER — 15% — N20107 001 FEB 05, 1993

AMINO ACIDS

INJECTABLE; INJECTION

/NOVAMINE/8.5%/
/KABIVITRUM/ /8.5%/ /N17957/002/
/AUG/09,/1982/

@ KABIVITRUM 8.5% N17957 002
AUG 09, 1982

TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER 10% N18931 003
AUG 23, 1984

/10%/ /N18931/004/
/APR/27,/1988/

/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /10%/ /N18931/003/
/AUG/23,/1984/

TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER 5.5% N18931 001
AUG 23, 1984

/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /5.5%/ /N18931/001/
/AUG/23,/1984/

TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER 8.5% N18931 002
AUG 23, 1984

/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /8.5%/ /N18931/002/
/AUG/23,/1984/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

>DLT> /AMINOSYN/II/7%/W//ELECTROLYTES/
>DLT> /ABBOTT/ /7%;102MG/100ML;45MG/100ML;/
>DLT> /522MG/100ML;410MG/100ML//N19437/006/
>DLT> /APR/03,/1986/
>ADD> @ ABBOTT 7%;102MG/100ML;45MG/100ML;
>ADD> 522MG/100ML;410MG/100ML N19437 006
>ADD> APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

>DLT> /AMINOSYN/II/3.5%/M/
>DLT> /ABBOTT/ /3.5%;36MG/100ML;97MG/100ML;/
>DLT> /120MG/100ML;49MG/100ML/ /N19437/007/
>DLT> /APR/03,/1986/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

>DLT> /AMINOSYN/II/3.5%/M/
>DLT> @ ABBOTT 3.5%;30MG/100ML;97MG/100ML;
>ADD> 120MG/100ML;49MG/100ML N19437 007
>ADD> APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

/AP/ /LYPHOMED/ /250MG/ML/ /N70522/001/
/JUN/17,/1986/

@ LYPHOMED 250MG/ML N70522 001
JUN 17, 1986

AMINOPHYLLINE

>DLT> /ENEMA;/RECTAL/
>DLT> /SUPPOPHYLLIN/
>DLT> /FISONS/ /300MG/5ML/ /N18232/001/
>DLT> /APR/02,/1982/
>ADD> @ FISONS 300MG/5ML N18232 001
>ADD> APR 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLINE

>DLT> /AP/ /BRISTOL/ /25MG/ML/ /N87431/001/
AP FUJISAWA 25MG/ML N88407 001
JAN 25, 1984

>ADD> @ 25MG/ML N87431 001
/AP/ /LYPHOMED/ /25MG/ML/ /N88407/001/
/JAN/25,/1984/

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

/AP/ /MSD/ /10MG/ML/ /N12704/001/
AP ZENECA 10MG/ML N12704 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ELAVIL		
/AA/	/MSD/	/10MG/	/N12703/001/
/AB/	/*/	/25MG/	/N12703/003/
/AB/		/50MG/	/N12703/004/
/AB/		/75MG/	/N12703/005/
/AB/		/100MG/	/N12703/006/
/AB/		/150MG/	/N12703/007/
AB	ZENECA	10MG	N12703 001
AB	+	25MG	N12703 003
AB		50MG	N12703 004
AB		75MG	N12703 005
AB		100MG	N12703 006
AB		150MG	N12703 007

AMOXICILLIN

CAPSULE; ORAL

	/TRIMOX/		
/AB/	/SQUIBB/	/250MG/	/N62098/001/
/AB/		/250MG/	/N62152/001/
/AB/		/500MG/	/N62098/002/
/AB/		/500MG/	/N62152/002/
	∂ APOTHECON	250MG	N62098 001
	∂	250MG	N62152 001
	∂	500MG	N62098 002
	∂	500MG	N62152 002

POWDER FOR RECONSTITUTION; ORAL

	AMOXICILLIN		
AB	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
AB		250MG/5ML	N62927 002 NOV 25, 1988
/BX/		/125MG/5ML/	/N62927/001/ /NOV/25,/1988/
/BX/		/250MG/5ML/	/N62927/002/ /NOV/25,/1988/

	/TRIMOX/		
/AB/	/SQUIBB/	/125MG/5ML/	/N62099/001/
/AB/		/125MG/5ML/	/N62154/001/
/AB/		/250MG/5ML/	/N62099/002/
/AB/		/250MG/5ML/	/N62154/002/
	∂ APOTHECON	125MG/5ML	N62099 001
	∂	125MG/5ML	N62154 001
	∂	250MG/5ML	N62099 002
	∂	250MG/5ML	N62154 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/CAPSULE;/ORAL/

/DELCOBESE/ LEMMON/		
	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83564/001/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83564/002/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83564/003/
	/5MG;5MG;5MG;5MG/	/N83564/004/
∂ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83564 001
∂	2.5MG;2.5MG;2.5MG;2.5MG	N83564 002
∂	3.75MG;3.75MG;3.75MG; 3.75MG	N83564 003
∂	5MG;5MG;5MG;5MG	N83564 004

/TABLET;/ORAL/

/DELCOBESE/ LEMMON/		
	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83563/004/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83563/003/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83563/002/
	/5MG;5MG;5MG;5MG/	/N83563/001/
∂ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83563 004
∂	2.5MG;2.5MG;2.5MG;2.5MG	N83563 003
∂	3.75MG;3.75MG;3.75MG; 3.75MG	N83563 002
∂	5MG;5MG;5MG;5MG	N83563 001

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	HANFORD	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993
AP		EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993
AP		EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993
/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/	/APR/04,/1985/
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/	/APR/04,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/	/JUN/24,/1986/
	∂ LILLY	EQ 500MG BASE/VIAL	N62565 001	APR 04, 1985
	∂	EQ 1GM BASE/VIAL	N62565 002	APR 04, 1985
	∂	EQ 2GM BASE/VIAL	N62565 003	JUN 24, 1986
	PENBRITIN-S /WYETH/AYERST/	/EQ/4GM/BASE/VIAL/	/N50072/006/	
	∂ WYETH AYERST	EQ 4GM BASE/VIAL	N50072 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
UNASYN

	/PFIZER/	/EQ/500MG/BASE/VIAL;/ /EQ/250MG/BASE/VIAL/	/N50608/003/	/DEC/31,/1986/
	∂ PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003	DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
/PRINCIPEN '250'/

/AB/	/SQUIBB/	/EQ 250MG BASE/	/N50056/001/
/AB/		/EQ 250MG BASE/	/N62157/002/
	∂ APOTHECON	EQ 250MG BASE	N50056 001
	∂	EQ 250MG BASE	N62157 002

/PRINCIPEN '500'/

/AB/	/SQUIBB/	/EQ 500MG BASE/	/N50056/002/
/AB/		/EQ 500MG BASE/	/N62157/001/
	∂ APOTHECON	EQ 500MG BASE	N50056 002
	∂	EQ 500MG BASE	N62157 001

POWDER FOR RECONSTITUTION; ORAL
/PRINCIPEN '125'/

/AB/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N60127/002/
/AB/		/EQ 125MG BASE/5ML/	/N62151/001/
	∂ APOTHECON	EQ 125MG BASE/5ML	N60127 002
	∂	EQ 125MG BASE/5ML	N62151 001

/PRINCIPEN '250'/

/AB/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N60127/001/
/AB/		/EQ 250MG BASE/5ML/	/N62151/002/
	∂ APOTHECON	EQ 250MG BASE/5ML	N60127 001
	∂	EQ 250MG BASE/5ML	N62151 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

/CAPSULE;/ORAL/
/PRINCIPEN/W/PROBENECID/

/*//SQUIBB/	/EQ/389MG/BASE;111MG/	/N50488/001/	
	/EQ/389MG/BASE;111MG/	/N62150/001/	
	∂ APOTHECON	EQ 389MG BASE;111MG	N50488 001
	∂	EQ 389MG BASE;111MG	N62150 001

ANISOTROPINE METHYLBROMIDE

>_DLT_>	/TABLET;/ORAL/			
>_DLT_>	/VALPIN/50/			
>_DLT_>	/DUPONT/	/50MG/	/N13428/001/	
>_ADD_>	∂ DUPONT	50MG	N13428 001	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 983

AP	FUJISAWA	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002 AUG 08, 1985
/AP/	/LYPHOMED/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS/ML;1 IU/ML/	/N18440/002/ /AUG/08,/1985/

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

/+//ADRIA/		/650MG;50MG/	/N88305/001/ /OCT/13,/1983/
+	SAVAGE	650MG;50MG	N88305 001 OCT 13, 1983

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MUTUAL PHARM	50MG	N73475 001 MAR 30, 1993
AB		100MG	N73476 001 MAR 30, 1993
AB	NOVOPHARM	50MG	N73315 001 MAY 28, 1993
AB		100MG	N73316 001 MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	MUTUAL PHARM	50MG;25MG	N73581 001 APR 29, 1993
AB		100MG;25MG	N73582 001 APR 29, 1993

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

/AZATHIOPRINE/

/AP/	/QUAD/	/EQ 100MG BASE/VIAL/	/N71056/001/ /JUN/08,/1988/
ə	QUAD	EQ 100MG BASE/VIAL	N71056 001 JUN 08, 1988

IMURAN

/AP/	/BURROUGHS/WELLCOME/	/EQ 100MG BASE/VIAL/	/N17391/001/
	BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

/MILES/		/EQ/2GM/BASE/VIAL/	/N62388/001/ /SEP/08,/1982/
ə	MILES	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
ə		/EQ/2GM/BASE/VIAL/	/N62417/001/ /OCT/12,/1982/
		EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
ə		/EQ/4GM/BASE/VIAL/	/N62388/003/ /SEP/08,/1982/
		EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
ə		/EQ/4GM/BASE/VIAL/	/N62417/003/ /OCT/12,/1982/
		EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM IN PLASTIC CONTAINER

> DLT >	/SQUIBB/	/10MG/ML/	/N50632/003/ /MAY/24,/1989/
> DLT >			
> ADD >	ə SQUIBB	10MG/ML	N50632 003 MAY 24, 1989
> ADD >			

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

> DLT >/AT/ /BURROUGHS/WELLCOME/ /400 UNITS/GM;1%;EQ 3.5MG BASE/GM;/
> DLT > /10,000 UNITS/GM/ /N50416/002/
> ADD > + BURROUGHS WELLCOME 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;
> ADD > 10,000 UNITS/GM N50416 002
> DLT > /ZINC BACITRACIN;NEOMYCIN SULFATE;POLYMYXIN B SULFATE %/
> DLT > /HYDROCORTISONE/
> DLT >/AT/ /PHARMAFAIR/ /400 UNITS/GM;1%;EQ 3.5MG BASE/GM;/
> DLT > /10,000 UNITS/GM/ /N62389/001/
> DLT > /JUL/02,/1982/
> ADD > ∂ PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;
> ADD > 10,000 UNITS/GM N62389 001
> ADD > JUL 02, 1982

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

> DLT > /BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/
> DLT >/AT/ /PHARMAFAIR/ /400 UNITS/GM;EQ 3.5MG BASE/GM;/
> DLT > /10,000 UNITS/GM/ /N62386/001/
> DLT > /SEP/09,/1982/
> ADD > ∂ PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM;
> ADD > 10,000 UNITS/GM N62386 001
> ADD > SEP 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

/PHARMADERM/ /400/UNITS/GM;EQ/3.5MG/BASE/GM;/
/5,000/UNITS/GM/ /N62167/001/

∂ PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM;
5,000 UNITS/GM N62167 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

/ADRIA/ /500MG/7.5ML/ /N18366/001/
/DEC/29,/1983/

SAVAGE 500MG/7.5ML N18366 001
DEC 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA PHARMACAPS 100MG N81297 001
JAN 29, 1993

BENZONATATE

CAPSULE; ORAL

TESSALON

AA FOREST LABS 100MG N11210 001

BENZTHIAZIDE

TABLET; ORAL

/AQUATAG/

/BP/ /SOLVAY/ /50MG/ /N16001/002/
∂ SOLVAY 50MG N16001 002

EXNA

/BP/+//ROBINS/AH/ /50MG/ /N12489/001/
+ ROBINS AH 50MG N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

/BEPADIN/

/AB/ /WALLACE/ /200MG/ /N19001/001/
/DEC/28,/1990/
/AB/ /300MG/ /N19001/002/
/DEC/28,/1990/
/AB/ /400MG/ /N19001/003/
/DEC/28,/1990/
∂ WALLACE 200MG N19001 001
DEC 28, 1990
∂ 300MG N19001 002
DEC 28, 1990
∂ 400MG N19001 003
DEC 28, 1990

VASCOR

/AB/ /JOHNSON/RW/ /200MG/ /N19002/001/
/DEC/28,/1990/
/AB/ /300MG/ /N19002/002/
/DEC/28,/1990/
/AB//+/ /400MG/ /N19002/003/
/DEC/28,/1990/
+ JOHNSON RW 400MG N19002 003
DEC 28, 1990
200MG N19002 001
DEC 28, 1990
300MG N19002 002
DEC 28, 1990

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N19136/001/ /JUN/26,/1984/	
	∂ PHARMADERM	EQ 0.05% BASE	N19136 001 JUN 26, 1984	

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N70274/001/ /AUG/12,/1985/	
	∂ PHARMADERM	EQ 0.05% BASE	N70274 001 AUG 12, 1985	

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N19140/001/ /SEP/04,/1984/	
	∂ PHARMADERM	EQ 0.05% BASE	N19140 001 SEP 04, 1984	

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18860/002/ /AUG/31,/1983/	
	∂ PHARMADERM	EQ 0.1% BASE	N18860 002 AUG 31, 1983	

LOTION; TOPICAL

BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18870/001/ /AUG/31,/1983/	>ADD > >ADD > >DLT > >DLT >
	∂ PHARMADERM	EQ 0.1% BASE	N18870 001 AUG 31, 1983	

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB	NMC	EQ 0.1% BASE	N70051 001 OCT 10, 1984	

BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18864/001/ /AUG/31,/1983/	
	∂ PHARMADERM	EQ 0.1% BASE	N18864 001 AUG 31, 1983	

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

/VALNAC/

/AB/	/NMC/	/EQ 0.1% BASE/	/N70051/001/ /OCT/10,/1984/

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

+ LEDERLE	10MG;6.25MG	N20186 002 MAR 26, 1993
	2.5MG;6.25MG	N20186 003 MAR 26, 1993
	5MG;6.25MG	N20186 001 MAR 26, 1993

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AA/	/ANABOLICS/	/4MG/	/N86187/001/	
	∂ ANABOLICS	4MG	N86187 001	
>DLT >/AA/	/NEWTRON/	/4MG/	/N86987/001/	
>ADD >	∂ NEWTRON	4MG	N86987 001	
AA	NYLOS TRADING	4MG	N85592 001	
/AA/	/TABLICAPS/	/4MG/	/N85592/001/	
/AA/	/ZENITH/	/4MG/	/N84351/001/	
	∂ ZENITH	4MG	N84351 001	

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL

CALDEROL

+ ORGANON	0.05MG	N18312 002	>ADD >	
	0.02MG	N18312 001	>ADD >	
/#//UPJOHN/	/0.05MG/	/N18312/002/	>DLT >	
	/0.02MG/	/N18312/001/	>DLT >	

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCIMAR

/AP/	/RHONE/POULENC/RORER//200 IU/ML/		/N17769/001/	
AP	+ RHONE POULENC RORER	200 IU/ML	N17769 001	

CALCITONIN, SALMON

INJECTABLE; INJECTION
MIACALCIN
/SANDOZ/ /100/IU/ML/ /N17808/001/ /JUL/03,/1986/
@ SANDOZ 100 IU/ML N17808 001 JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
> ADD > ENDOSOL EXTRA
> ADD > AT @ ALLERGAN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001 NOV 27, 1991
> DLT > /ENDOSOL PLUS/
> DLT > /AT/ /ALLERGAN/ /0.154MG/ML;0.92MG/ML;0.184MG/ML;/ /0.2MG/ML;0.38MG/ML;2.1MG/ML;/ /7.14MG/ML;0.42MG/ML/ /N20079/001/ /NOV/27,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
> ADD > ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
> ADD > @ MCGAW 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001 JUN 10, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
/AP/ /LYPHOMED/ /EQ 90MG CALCIUM/5ML/ /N89373/001/ /APR/30,/1987/
@ LYPHOMED EQ 90MG CALCIUM/5ML N89373 001 APR 30, 1987

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION
GEOPEN
> DLT >/AP/ /ROERIG/ /EQ 1GM BASE/VIAL/ /N50306/001/
> DLT >/AP/ /EQ 2GM BASE/VIAL/ /N50306/004/
> DLT >/AP/ /EQ 5GM BASE/VIAL/ /N50306/002/
> DLT >/AP/ /EQ 10GM BASE/VIAL/ /N50306/006/
> ADD > ROERIG EQ 1GM BASE/VIAL N50306 001
> ADD > EQ 2GM BASE/VIAL N50306 004
> ADD > EQ 5GM BASE/VIAL N50306 002
> ADD > EQ 10GM BASE/VIAL N50306 006

PYOPEN
> DLT >/AP/ /SMITHKLINE/BEECHAM/ /EQ 1GM BASE/VIAL/ /N50298/001/
> DLT >/AP/ /EQ 2GM BASE/VIAL/ /N50298/002/
> DLT >/AP/ /EQ 5GM BASE/VIAL/ /N50298/003/
> DLT >/AP/ /EQ 10GM BASE/VIAL/ /N50298/006/
> ADD > @ SMITHKLINE BEECHAM EQ 1GM BASE/VIAL N50298 001
> ADD > @ EQ 2GM BASE/VIAL N50298 002
> ADD > @ EQ 5GM BASE/VIAL N50298 003
> ADD > @ EQ 10GM BASE/VIAL N50298 006
> DLT > /EQ/20GM/BASE/VIAL/ /N50298/007/
> ADD > @ EQ 20GM BASE/VIAL N50298 007

CARBINOXAMINE MALEATE

/TABLET;/ORAL/
/CLISTIN/
/JOHNSON/RW/ /4MG/ /N08915/001/
@ JOHNSON RW 4MG N08915 001

CARISOPRODOL

/CAPSULE;/ORAL/
/SOMA/
/WALLACE/ /250MG/ /N11792/003/
@ WALLACE 250MG N11792 003

TABLET; ORAL
CARISOPRODOL
/AA/ /PIONEER/PHARMS/ /350MG/ /N89390/001/ /OCT/13,/1988/
@ PIONEER PHARMS 350MG N89390 001 OCT 13, 1988

/RELA/
/AA/ /SCHERING/ /350MG/ /N12155/001/
@ SCHERING 350MG N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPTIPRESS		
	/BURROUGHS/WELLCOME/	/1%/	/N19972/001/ /MAY/23,/1990/
	OTSUKA	1%	N19972 001 MAY 23, 1990

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL		
>ADD<	+ LILLY	EQ 10GM BASE/VIAL	N50504 004

CEFMENOXIME HYDROCHLORIDE

	/INJECTABLE;/INJECTION/		
	/CEFMAX/		
	/TAP/	/EQ/500MG/BASE/VIAL/	/N50571/001/ /DEC/30,/1987/
		/EQ/1GM/BASE/VIAL/	/N50571/002/ /DEC/30,/1987/
		/EQ/2GM/BASE/VIAL/	/N50571/003/ /DEC/30,/1987/
	∂ TAP	EQ 500MG BASE/VIAL	N50571 001 DEC 30, 1987
	∂	EQ 1GM BASE/VIAL	N50571 002 DEC 30, 1987
	∂	EQ 2GM BASE/VIAL	N50571 003 DEC 30, 1987

CEFONICID SODIUM

INJECTABLE; INJECTION

	MONOCID		
>DLT<	/SMITHKLINE/BEECHAM/	/EQ/2GM/BASE/VIAL/	/N50579/003/ /MAY/23,/1984/
>DLT<			
>ADD<	∂ SMITHKLINE BEECHAM	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984
>ADD<			

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

	CEFOTAN		
AP	STUART	EQ 1GM BASE/VIAL	N50588 001 DEC 27, 1985
AP		EQ 2GM BASE/VIAL	N50588 002 DEC 27, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

	CEFOTAN		
AP	ZENECA	EQ 1GM BASE/VIAL	N63293 001 APR 29, 1993
AP		EQ 2GM BASE/VIAL	N63293 002 APR 29, 1993

CEFOTIAM HYDROCHLORIDE

	/INJECTABLE;/INJECTION/		
	/CERADON/		
	/TAKEDA/	/EQ/1GM/BASE/VIAL/	/N50601/001/ /DEC/30,/1988/
	∂ TAKEDA	EQ 1GM BASE/VIAL	N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

	MEFOXIN IN PLASTIC CONTAINER		
	MERCK	EQ 20MG BASE/ML	N63182 001 JAN 25, 1993
		EQ 40MG BASE/ML	N63182 002 JAN 25, 1993

CEFPIRAMIDE SODIUM

	/INJECTABLE;/INJECTION/		
	/CEFPIRAMIDE/SODIUM/		
	/WYETH/AYERST/	/EQ/1GM/BASE/VIAL/	/N50633/002/ /JAN/31,/1989/
		/EQ/2GM/BASE/VIAL/	/N50633/003/ /JAN/31,/1989/
		/EQ/10GM/BASE/VIAL/	/N50633/005/ /JAN/31,/1989/
	∂ WYETH AYERST	EQ 1GM BASE/VIAL	N50633 002 JAN 31, 1989
	∂	EQ 2GM BASE/VIAL	N50633 003 JAN 31, 1989
	∂	EQ 10GM BASE/VIAL	N50633 005 JAN 31, 1989

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER	EQ 10MG BASE/ML	N63221 001 APR 29, 1993
AP		EQ 20MG BASE/ML	N63221 002 APR 29, 1993
AP		EQ 40MG BASE/ML	N63221 003 APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP	GLAXO	EQ 10MG BASE/ML	N50634 001 APR 28, 1989
AP		EQ 20MG BASE/ML	N50634 002 APR 28, 1989
AP		EQ 40MG BASE/ML	N50634 003 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	FUJISAWA	EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

/ROCHE/		/EQ/10MG/BASE/ML/	/N50624/001/ /FEB/11,/1987/
ə	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AP	MARSAM	EQ 750MG BASE/VIAL	N64035 001 FEB 26, 1993
AP		EQ 1.5GM BASE/VIAL	N64035 002 FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	N64036 001 FEB 26, 1993

KEFUROX

AP	LILLY	EQ 7.5GM BASE/VIAL	N62591 003 DEC 17, 1987

ZINACEF

AP	GLAXO	EQ 7.5GM BASE/VIAL	N50558 004 OCT 23, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND

/+//MISSION/PHARMA/		/2.5GM/PACKET/	/N18757/002/ /DEC/28,/1982/
ə	MISSION PHARMA	2.5GM/PACKET	N18757 002 DEC 28, 1982

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
/CEPHAPIRIN SODIUM/

> DLT >				
> DLT >	/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/ /NOV/17,/1986/
> DLT >				
> DLT >	/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/ /NOV/17,/1986/
> DLT >				
> DLT >	/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/ /NOV/17,/1986/
> DLT >				
> DLT >	/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/ /NOV/17,/1986/
> DLT >				
> ADD >	ə	LYPHOMED	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
> ADD >				
> ADD >	ə		EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
> ADD >				
> ADD >	ə		EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
> ADD >				
> ADD >	ə		EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986
> ADD >				

CHLORDIAZEPOXIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/LIBRELEASE/

/+//ROCHE/		/30MG/	/N17813/001/ /SEP/12,/1983/
ə	ROCHE	30MG	N17813 001 SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

/AB/	/PIONEER/PHARMS/		/25MG/	/N89558/001/ /JUL/15,/1988/
ə	PIONEER PHARMS		25MG	N89558 001 JUL 15, 1988

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

AB	ROCHE	5MG	N12249 002
AB		10MG	N12249 001
AB		25MG	N12249 003
AB		25MG	N85475 001
AB	+ ROCHE	25MG	N85475 001
	∂	5MG	N12249 002
	∂	10MG	N12249 001
	∂	25MG	N12249 003

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

AB	MSD	150MG;250MG	N16016 001

ALDOCLOR-250

AB	MSD	250MG;250MG	N16016 002
	+ MSD	250MG;250MG	N16016 002

METHYLDOPA AND CHLOROTHIAZIDE

AB	PAR	150MG;250MG	N70783 001 NOV 06, 1987
AB		250MG;250MG	N70654 001 NOV 06, 1987
	∂ PAR	150MG;250MG	N70783 001 NOV 06, 1987
	∂	250MG;250MG	N70654 001 NOV 06, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

TACE

	∂ MERRELL DOW	72MG	N16235 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

> DLT > AP	BEL MAR	10MG/ML	N80821 001
> ADD >	∂ BEL MAR	10MG/ML	N80821 001
> DLT > AP	STERIS	100MG/ML	N86095 001
> ADD >	STERIS	100MG/ML	N86095 001
> DLT >	PYRIDAMAL 100		
> DLT > AP	BEL MAR	100MG/ML	N83733 001
> ADD >	∂ BEL MAR	100MG/ML	N83733 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

> DLT > AA	NEWTRON	4MG	N86519 001
> ADD >	∂ NEWTRON	4MG	N86519 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP	LYPHOMED	25MG/ML	N84911 001
	∂ LYPHOMED	25MG/ML	N84911 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AA	PHARM BASICS	50MG	N89052 001 JUN 01, 1987
	∂ PHARM BASICS	50MG	N89052 001 JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

	CIBA	25MG;200MG	N19451 002 DEC 31, 1987
		25MG;100MG	N19451 001 DEC 31, 1987
	∂ CIBA	25MG;100MG	N19451 001 DEC 31, 1987
	∂	25MG;200MG	N19451 002 DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	PIONEER PHARMS	250MG	N89592 001 JAN 06, 1989
AA		500MG	N89948 001 JAN 06, 1989
	∂ PIONEER PHARMS	250MG	N89592 001 JAN 06, 1989
	∂	500MG	N89948 001 JAN 06, 1989

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

CATARASE			
+ IOLAB	300 UNITS/VIAL	N16938 001	
	/150/UNITS/VIAL/	/N18121/001/	
∂	150 UNITS/VIAL	N18121 001	
	/300/UNITS/VIAL/	/N16938/001/	

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN			
+ JOHNSON RW	1MG/ML	N20229 001	
		FEB 26, 1993	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN				
AB + UPJOHN	EQ 75MG BASE	N50162 001		
/AB/#/	/EQ 75MG BASE/	/N61809/001/		
AB +	EQ 150MG BASE	N50162 002		
/AB/#/	/EQ 150MG BASE/	/N61809/002/		
∂	EQ 75MG BASE	N61809 001		
∂	EQ 150MG BASE	N61809 002		

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE			
AP + UPJOHN	EQ 150MG BASE/ML	N50441 001	
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%			
> DLT > /AP/ /LYPHOMED/	/EQ 12MG BASE/ML/	/N50636/001/	
> DLT >		/DEC/22,/1989/	
> ADD > ∂ LYPHOMED	EQ 12MG BASE/ML	N50636 001	
> ADD >		DEC 22, 1989	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL				
/AB/ /BIOCRAFT/	/0.1MG/	/N70747/001/		
		/MAR/26,/1986/		
/AB/	/0.2MG/	/N70702/001/		
		/MAR/26,/1986/		
/AB/	/0.3MG/	/N70659/001/		
		/MAR/26,/1986/		
∂ BIOCRAFT	0.1MG	N70747 001		
		JUL 08, 1986		
∂	0.2MG	N70702 001		
		JUL 08, 1986		
∂	0.3MG	N70659 001		
		JUL 08, 1986		

CLOTRIMAZOLE

/CREAM;/VAGINAL/			
/GYNE-LOTRIMIN/			
/BT/ /SCHERING/	/1%/	/N18052/001/	
/MYCELEX-G/			
/BT/ /MILES/	/1%/	/N18236/001/	
/TABLET;/VAGINAL/			
/GYNE-LOTRIMIN/			
/BT/ /SCHERING/	/100MG/	/N17717/001/	
/MYCELEX-G/			
/BT/ /MILES/	/100MG/	/N18182/001/	

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHAR			
> DLT > /AP/ /ARMOUR/	/25 UNITS/VIAL/	/N07504/002/	
> DLT > /AP/	/40 UNITS/VIAL/	/N07504/003/	
> ADD > AP RHONE POULENC RORER	25 UNITS/VIAL	N07504 002	
> ADD > AP	40 UNITS/VIAL	N07504 003	
H.P. ACTHAR GEL			
> DLT > /BC/ /ARMOUR/	/40/UNITS/ML/	/N08372/006/	
> DLT > /BC/#/	/80/UNITS/ML/	/N08372/008/	
> ADD > BC RHONE POULENC RORER	40 UNITS/ML	N08372 006	
> ADD > BC +	80 UNITS/ML	N08372 008	
> DLT > /PURIFIED/CORTROPHIN/GEL/			
> DLT > /BC/ /ORGANON/	/40/UNITS/ML/	/N08975/001/	
> DLT > /BC/	/80/UNITS/ML/	/N08975/002/	
> ADD > ∂ ORGANON	40 UNITS/ML	N08975 001	
> ADD > ∂	80 UNITS/ML	N08975 002	

CORTICOTROPIN-ZINC HYDROXIDE

>DLT>	/INJECTABLE;/INJECTION/			
>DLT>	/CORTROPHIN-ZINC/			
>DLT>	/+//ORGANON/	/40/UNITS/ML/	/N09854/001/	
>ADD>	@ ORGANON	40 UNITS/ML	N09854 001	

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

/BP/	/HEATHER/	/25MG/	/N85736/001/	
	@ HEATHER	25MG	N85736 001	

CROMOLYN SODIUM

>DLT>	/SOLUTION;/NASAL/			
>DLT>	/NASALCROM/			
>DLT>	/FISONS/	/4%/	/N18306/001/	
>DLT>			/MAR/18;/1983/	
>ADD>	SPRAY, METERED; NASAL			
>ADD>	NASALCROM			
>ADD>	+ FISONS	5.2MG/INH	N18306 001	
>ADD>			MAR 18, 1983	

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

>DLT>/AP/	/DELL/	/0.03MG/ML/	/N80689/001/	
>ADD>	DELL	0.03MG/ML	N80689 001	
/AP/	/FUJISAWA/	/1MG/ML/	/N83075/001/	
	@ FUJISAWA	1MG/ML	N83075 001	
>DLT>	/RUBIVITE/			
>DLT>/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/	
>DLT>/AP/		/0.1MG/ML/	/N10791/002/	
>DLT>/AP/		/1MG/ML/	/N10791/003/	
>DLT>		/0.05MG/ML/	/N10791/001/	
>DLT>		/0.12MG/ML/	/N10791/005/	
>ADD>	@ BEL MAR	0.03MG/ML	N10791 004	
>ADD>	@	0.05MG/ML	N10791 001	
>ADD>	@	0.1MG/ML	N10791 002	
>ADD>	@	0.12MG/ML	N10791 005	
>ADD>	@	1MG/ML	N10791 003	

CYCLACILLIN

	/POWDER/FOR/RECONSTITUTION;/ORAL/			
	/CYCLAPEN-W/			
	/+//WYETH/AYERST/	/500MG/5ML/	/N50508/003/	
		/125MG/5ML/	/N50508/001/	
		/250MG/5ML/	/N50508/002/	
	@ WYETH AYERST	125MG/5ML	N50508 001	
	@	250MG/5ML	N50508 002	
	@	500MG/5ML	N50508 003	

CYCLIZINE LACTATE

	/INJECTABLE;/INJECTION/			
	/MAREZINE/			
	/BURROUGHS/WELLCOME/	/50MG/ML/	/N09495/001/	
	@ BURROUGHS WELLCOME	50MG/ML	N09495 001	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	INVAMED	10MG	N73683 001
			FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
NEOSAR

AP	ADRIA	100MG/VIAL	N40015 001
			APR 29, 1993
AP		200MG/VIAL	N40015 002
			APR 29, 1993
AP		500MG/VIAL	N40015 003
			APR 29, 1993
AP		1GM/VIAL	N40015 004
			APR 29, 1993
AP		2GM/VIAL	N40015 005
			APR 29, 1993

DESIPRAMINE HYDROCHLORIDE

/CAPSULE;/ORAL/			
/PERTOFRANE/			
/+//RHONE/POULENC/RORER/	/50MG/	/N13621/002/	
	/25MG/	/N13621/001/	
@ RHONE POULENC RORER	25MG	N13621 001	
@	50MG	N13621 002	

DESLANOSIDE

/INJECTABLE;/INJECTION/
/CEDILANID-D/
/SANDOZ/ /0.2MG/ML/ /N09282/002/
ə SANDOZ 0.2MG/ML N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP
RHONE POULENC RORER 0.01MG/INH N17922 002 FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE

/INJECTABLE;/INJECTION/
/PERCORTEN/
/CIBA/ /25MG/ML/ /N08822/001/
ə CIBA 25MG/ML N08822 001

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
AA BARRE 0.5MG/5ML N88997 001 OCT 10, 1986
/AA/ /NASKA/ /0.5MG/5ML/ /N88997/001/ /OCT/10,/1986/

SOLUTION; ORAL
/DEXAMETHASONE/
/ROXANE/ /0.5MG/5ML/ /N88248/001/ /SEP/01,/1983/
ə ROXANE 0.5MG/5ML N88248 001 SEP 01, 1983

TABLET; ORAL
DECADRON
AB MSD 0.5MG N11664 001
AB + 0.75MG N11664 002
AB 1.5MG N11664 003
AB 4MG N11664 005
/BP/ /0.5MG/ /N11664/001/
/BP/+/ /0.75MG/ /N11664/002/
/BP/ /1.5MG/ /N11664/003/
/BP/ /4MG/ /N11664/005/

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE
AB ROXANE 0.5MG N84611 001
AB 0.75MG N84613 001
AB 1.5MG N84610 001
AB 4MG N84612 001
/BP/ /0.5MG/ /N84611/001/
/BP/ /0.75MG/ /N84613/001/
/BP/ /1.5MG/ /N84610/001/
/BP/ /4MG/ /N84612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
>DLT> /DEXASPORIN/
>DLT>/AT/ /PHARMAFAIR/ /0.1%;EQ 3.5MG BASE/GM;/
>DLT> /10,000 UNITS/GM/ /N62411/001/
>DLT> /MAY/16,/1983/
>ADD> ə PHARMAFAIR 0.1%;EQ 3.5MG BASE/GM;
>ADD> 10,000 UNITS/GM N62411 001
>ADD> MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC
>DLT> /DEXASPORIN/
>DLT>/AT/ /PHARMAFAIR/ /0.1%;EQ 3.5MG BASE/ML;/
>DLT> /10,000 UNITS/ML/ /N62428/001/
>DLT> /MAY/18,/1983/
>ADD> ə PHARMAFAIR 0.1%;EQ 3.5MG BASE/ML;
>ADD> 10,000 UNITS/ML N62428 001
>ADD> MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
>DLT>/AP/ /BEL/MAR/ /EQ 4MG PHOSPHATE/ML/ /N84752/001/
>ADD> ə BEL MAR EQ 4MG PHOSPHATE/ML N84752 001
>DLT>/AP/ /BRISTOL/ /EQ 4MG PHOSPHATE/ML/ /N87065/001/
>ADD> ə FUJISAWA EQ 4MG PHOSPHATE/ML N87065 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
/DEXAMPEX/
/AA/ /LEMMON/ /5MG/ /N83735/001/
/AA/ /10MG/ /N83735/002/
ə LEMMON 5MG N83735 001
ə 10MG N83735 002

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

>DLT>	FERNDEX			
>DLT>/AA/	/FERNDALE/	/5MG/		/N84001/001/
>ADD>	@ FERNDALE	5MG		N84001 001

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

>DLT>/AP/	/ABBOTT/	/500MG/ML/		/N19445/001/
>DLT>				/JUN/03,/1986/
>ADD>	@ ABBOTT	500MG/ML		N19445 001
>ADD>				JUN 03, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	MCGAW	5GM/100ML;31MG/100ML;130MG/100ML;		
>ADD>		26MG/100ML;320MG/100ML	N19873 001	
>ADD>			JUN 10, 1993	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	MCGAW	5GM/100ML;30MG/100ML;97MG/100ML;		
>ADD>		220MG/100ML;140MG/100ML	N19844 001	
>ADD>			JUN 10, 1993	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML;		
>ADD>		280MG/100ML;91MG/100ML	N19870 001	
>ADD>			JUN 10, 1993	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

>DLT>	/HYPAQUE-M,75%/			
>DLT>	/STERLING/	/50%;25%/		/N16226/003/
>ADD>	@ STERLING	50%;25%		N10220 003
>DLT>	/HYPAQUE-M,90%/			
>DLT>	/STERLING/	/60%;30%/		/N16226/002/
>ADD>	@ STERLING	60%;30%		N10220 002

DIATRIZOATE SODIUM

>DLT>	/SOLUTION;URETERAL/			
>DLT>	/HYPAQUE/SODIUM/20%/			
>DLT>	/STERLING/	/20%/		/N09561/002/
>ADD>	@ STERLING	20%		N09561 002

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	MARSAM	5MG/ML		N72370 001
				JAN 29, 1993
AP		5MG/ML		N72371 001
				JAN 29, 1993
AP		5MG/ML		N72397 001
				JAN 29, 1993

VALIUM

>DLT>/AP/	/ROCHE/	/5MG/ML/		/N16087/001/
>ADD> AP	+ ROCHE	5MG/ML		N16087 001

INJECTABLE; INTRAVENOUS

DIZAC

>ADD>	+ KABI	5MG/ML		N19287 001
>ADD>				JUN 18, 1993

TABLET; ORAL

DIAZEPAM

>ADD>	@ FERNDALE	2MG		N70903 001
>ADD>				APR 01, 1987
>ADD>	@	5MG		N70904 001
>ADD>				APR 01, 1987
>ADD>	@	10MG		N70905 001
>ADD>				APR 01, 1987
>DLT>/AB/	/PHARM/BASICS/	/2MG/		/N70903/001/
>DLT>				/APR/01,/1987/
>DLT>/AB/		/5MG/		/N70904/001/
>DLT>				/APR/01,/1987/
>DLT>/AB/		/10MG/		/N70905/001/
>DLT>				/APR/01,/1987/

DIAZEPAM

TABLET; ORAL

DIAZEPAM

/AB/	/ZENITH/	/2MG/	/N70360/001/ /SEP/04,/1985/	
/AB/		/5MG/	/N70361/001/ /SEP/04,/1985/	
	ə ZENITH	2MG	N70360 001 SEP 04, 1985	
	ə	5MG	N70361 001 SEP 04, 1985	

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

+	BAKER NORTON	50MG	N17425 001
/+//MEDCL/MKTG/		/50MG/	/N17425/001/

INJECTABLE; INJECTION

DIAZOXIDE

/AP/	/QUAD/	/15MG/ML/	/N71908/001/ /JAN/26,/1988/	
	ə QUAD	15MG/ML	N71908 001 JAN 26, 1988	

HYPERSTAT

/AP/	/SCHERING/	/15MG/ML/	/N16996/001/	
	SCHERING	15MG/ML	N16996 001	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

VOLTAREN

	/CIBA/	/0.1%/	/N20037/001/ /MAR/28,/1991/	
	CIBA VISION	0.1%	N20037 001 MAR 28, 1991	

DICUMAROL

TABLET; ORAL

DICUMAROL

>DLT>	/+//ABBOTT/	/50MG/	/N05545/004/	
>ADD>	ə ABBOTT	50MG	N05545 004	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

/AB/	/PIONEER/PHARMS/	/10MG/	/N89361/001/ /JAN/10,/1989/	
	ə PIONEER PHARMS	10MG	N89361 001 JAN 10, 1989	

TABLET; ORAL

DICYCLOMINE HCL

/AB/	/PIONEER/PHARMS/	/20MG/	/N88585/001/ /AUG/20,/1986/	
	ə PIONEER PHARMS	20MG	N88585 001 AUG 20, 1986	

DIETHYLSTILBESTROL

>DLT>	/INJECTABLE;/INJECTION/			
>DLT>	/STILBESTROL/			
>DLT>	/SQUIBB/	/0.2MG/ML/	/N04056/003/	
>DLT>		/0.5MG/ML/	/N04056/004/	
>DLT>		/1MG/ML/	/N04056/005/	
>DLT>		/5MG/ML/	/N04056/006/	
>ADD>	ə SQUIBB	0.2MG/ML	N04056 003	
>ADD>	ə	0.5MG/ML	N04056 004	
>ADD>	ə	1MG/ML	N04056 005	
>ADD>	ə	5MG/ML	N04056 006	

>DLT>	/SUPPOSITORY;/VAGINAL/			
>DLT>	/STILBESTROL/			
>DLT>	/+//SQUIBB/	/0.1MG/	/N04056/001/	
>DLT>	/+/	/0.5MG/	/N04056/002/	
>ADD>	ə SQUIBB	0.1MG	N04056 001	
>ADD>	ə	0.5MG	N04056 002	

TABLET, DELAYED RELEASE; ORAL

STILBETIN

>DLT>	/BE/ /SQUIBB/	/0.1MG/	/N04056/011/	
>ADD>	ə SQUIBB	0.1MG	N04056 011	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>ADD >	BC + CARDERM	180MG	
>ADD >			
>ADD >	BC +	240MG	
>ADD >			
>ADD >	+	120MG	
>ADD >			
>ADD >	+	300MG	
>ADD >			
>DLT >	/BC/+//MARION/MERRELL/DOW/	/180MG/	
>DLT >			
>DLT >	/BC/+/	/240MG/	
>DLT >			
>DLT >	/+/	/120MG/	
>DLT >			
>DLT >	/+/	/300MG/	
>DLT >			

TABLET; ORAL

DILTIAZEM HCL

AB	APOTHECON	30MG	N74051 001 MAR 31, 1993
AB		60MG	N74051 002 MAR 31, 1993
AB		90MG	N74051 003 MAR 31, 1993
AB		120MG	N74051 004 MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

/AA/	/LEMMON/	/25MG/	/N85874/001/
/AA/		/50MG/	/N85874/002/
	@ LEMMON	25MG	N85874 001
	@	50MG	N85874 002

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

>DLT >/AP/	/BEL/MAR/	/10MG/ML/	/N80822/001/
>ADD >	@ BEL MAR	10MG/ML	N80822 001
>DLT >/AP/	/BRISTOL/	/10MG/ML/	/N87066/001/
>ADD >	@ FUJISAWA	10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE

>DLT >	/CAPSULE;/EXTENDED/RELEASE;/ORAL/			
>DLT >	/HISPRIL/			
>DLT >	/+//SMITHKLINE/BEECHAM/	/5MG/		/N11945/001/
>ADD >	@ SMITHKLINE BEECHAM	5MG		N11945 001

DIVALPROEX SODIUM

>DLT >	/TABLET;/DELAYED/RELEASE;/ORAL/			
>DLT >	/DEPAKOTE/CP/			
>DLT >	/ABBOTT/	/EQ/250MG/BASE/		/N19794/001/
>DLT >				/JUL/11,/1990/
>DLT >		/EQ/500MG/BASE/		/N19794/002/
>ADD >	@ ABBOTT	EQ 250MG BASE		/JUL/11,/1990/
>ADD >				N19794 001
>ADD >	@	EQ 500MG BASE		JUL 11, 1990
>ADD >				N19794 002
				JUL 11, 1990

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

>DLT >/AP/	/BRISTOL/	/40MG/ML/	/N18549/001/
>DLT >			/MAR/11,/1983/
>ADD >	@ FUJISAWA	40MG/ML	N18549 001
>ADD >			MAR 11, 1983
/AP/	/LYPHOMED/	/40MG/ML/	/N70012/001/
	@ LYPHOMED	40MG/ML	/JUN/12,/1985/
			N70012 001
			JUN 12, 1985

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE MONOHYDRATE

>DLT >	/+//MEDICOPHARMA/	/EQ/100MG/BASE/		/N50641/001/
>DLT >				/DEC/29,/1989/
>ADD >	+ VINTAGE	EQ 100MG BASE		N50641 001
>ADD >				DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/ /OCT/19,/1984/	
/AB/		/EQ 100MG BASE/	/N62442/001/ /DEC/22,/1983/	
	ə PAR	EQ 50MG BASE	N62434 001 OCT 19, 1984	
	ə	EQ 100MG BASE	N62442 001 DEC 22, 1983	

TABLET; ORAL
DOXYCYCLINE HYCLATE

/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/ /MAY/11,/1983/	
	ə HEATHER	EQ 100MG BASE	N62462 001 MAY 11, 1983	

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/ /AUG/17,/1988/	
	ə QUAD	2.5MG/ML	N71941 001 AUG 17, 1988	
/AP/	/SMITH/NEPHEW/SOLOPAK/	2.5MG/ML/	/N71754/001/ /SEP/06,/1988/	
/AP/		/2.5MG/ML/	/N71755/001/ /SEP/06,/1988/	
AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988	
AP		2.5MG/ML	N71755 001 SEP 06, 1988	

EDETATE DISODIUM

INJECTABLE; INJECTION

>DLT>	/DISODIUM EDETATE/			
>DLT>/AP/	/STERIS/	/150MG/ML/	/N84356/001/	
>ADD>	ə STERIS	150MG/ML	N84356 001	

EFLORNITHINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
ORNIDYL

/MERRELL/DOW/	/200MG/ML/	/N19879/002/ /NOV/28,/1990/	
ə MERRELL DOW	200MG/ML	N19879 002 NOV 28, 1990	

ENCAINIDE HYDROCHLORIDE

>DLT>	/CAPSULE;/ORAL/			
>DLT>	ENKAID			
>DLT>	/+//BRISTOL/	/50MG/	/N18981/004/ /DEC/24,/1986/	
>DLT>		/25MG/	/N18981/002/ /DEC/24,/1986/	
>DLT>		/35MG/	/N18981/003/ /DEC/24,/1986/	
>ADD>	ə BRISTOL	25MG	N18981 002 DEC 24, 1986	
>ADD>	ə	35MG	N18981 003 DEC 24, 1986	
>ADD>	ə	50MG	N18981 004 DEC 24, 1986	

ENOXACIN

TABLET; ORAL
PENETREX

/+//PARKE/DAVIS/	/400MG/	/N19616/005/ /DEC/31,/1991/	
	/200MG/	/N19616/004/ /DEC/31,/1991/	
+ RHONE POULENC RORER	400MG	N19616 005 DEC 31, 1991	
	200MG	N19616 004 DEC 31, 1991	

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

RHONE POULENC RORER	30MG/0.3ML	N20164 001 MAR 29, 1993	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	STERLING WINTHROP	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP		0.02MG/ML;2%	N40057 001 FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE

> DLT > /AP/	/BEL/MAR/	/0.01MG/ML;1%/	/N80826/001/
> DLT > /AP/		/0.01MG/ML;2%/	/N80757/001/
> ADD >	ə BEL MAR	0.01MG/ML;1%	N80820 001
> ADD >	ə	0.01MG/ML;2%	N80757 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

> DLT >	/INJECTABLE;/INJECTION/		
> DLT >	/PROCAINE/HCL/W//EPINEPHRINE/		
> DLT >	/BEL/MAR/	/0.02MG/ML;1%/	/N80758/001/
> DLT >		/0.02MG/ML;2%/	/N80759/001/
> ADD >	ə BEL MAR	0.02MG/ML;1%	N80758 001
> ADD >	ə	0.02MG/ML;2%	N80759 001

ERGOLOID MESYLATES

TABLET; ORAL

HYDERGINE

	/SANDOZ/	/0.5MG/	/N17993/003/
	ə SANDOZ	0.5MG	N17993 003

TABLET; SUBLINGUAL

HYDROGENATED ERGOT ALKALOIDS

/AA/	/ZENITH/	/0.5MG/	/N87186/001/
	ə ZENITH	0.5MG	N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

/AA/	/FISONS/	/2MG/	/N87693/001/ /FEB/24,/1983/
AA	LOTUS	2MG	N87693 001 FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

/ERYC/SPRINKLES/

/*//FAULDING/		/125MG/	/N50593/001/ /JUL/22,/1985/
ə FAULDING		125MG	N50593 001 JUL 22, 1985

GEL; TOPICAL

ERYGEL

/AT/	/HERBERT/	/2%/	/N50617/001/ /OCT/21,/1987/
AT	+ HERBERT	2%	N50617 001 OCT 21, 1987

ERYTHROMYCIN

AT	STIEFEL	2%	N63211 001 JAN 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

/AT/	/PHARMADERM/	/5MG/GM/	/N62446/001/ /SEP/26,/1983/
	ə PHARMADERM	5MG/GM	N62446 001 SEP 26, 1983
> DLT > /AT/	/PHARMAFAIR/	/5MG/GM/	/N62481/001/ /APR/05,/1984/
> DLT >			
> ADD >	ə PHARMAFAIR	5MG/GM	N62481 001 APR 05, 1984
> ADD >			

/POWDER;/FOR/RX/COMPOUNDING/

/ERYTHROMYCIN/

	/PADDOCK/	/100%/	/N50610/001/ /NOV/07,/1986/
	ə PADDOCK	100%	N50610 001 NOV 07, 1986

SOLUTION; TOPICAL

ERYTHRA-DERM

AT	PADDOCK	2%	N62687 001 FEB 05, 1988

ERYTHROMYCIN

AT	BARRE	2%	N62957 001 JUL 21, 1988
/AT/	/NASKA/	/2%/	/N62957/001/ /JUL/21,/1988/
/AT/	/ETS-2%/ /PADDOCK/	/2%/	/N62687/001/ /FEB/05,/1988/

ERYTHROMYCIN ESTOLATE

ESTROGENS, CONJUGATED

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
@ LIFE LABORATORIES EQ 250MG BASE/5ML N62362 001
DEC 17, 1982

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE
>DLT >/AP/ /LYPHOMED/ /EQ 500MG BASE/VIAL/ /N62604/001/
>DLT > /NOV/24,/1986/
>DLT >/AP/ /EQ 1GM BASE/VIAL/ /N62604/002/
>DLT > /NOV/24,/1986/
>ADD > @ LYPHOMED EQ 500MG BASE/VIAL N62604 001
>ADD > NOV 24, 1986
>ADD > @ EQ 1GM BASE/VIAL N62604 002
>ADD > NOV 24, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
+ ANAQUEST 10MG/ML N19386 001
AUG 15, 1988
+ 250MG/ML N19386 002
DEC 31, 1986
/DUPONT/ /10MG/ML/ /N19386/001/
/AUG/15,/1988/
/250MG/ML/ /N19386/002/
/DEC/31,/1986/

ESTRADIOL

TABLET; ORAL
ESTRACE
>ADD > BRISTOL MYERS SQUIBB 0.5MG N81295 001
>ADD > JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN
+ AYERST 0.625MG/GM N20216 001
/+//WYETH/AYERST/ /0.625MG/GM/ /N83273/001/

ESTROGENS, CONJUGATED

TABLET; ORAL
PREMARIN
+ WYETH AYERST 1.25MG N04782 001
/+/ /2.5MG/ /N04782/002/
/1.25MG/ /N04782/001/
2.5MG N04782 002

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21
AB ROBERTS 0.035MG;1MG N71480 001
APR 12, 1988
/AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ /N71480/001/
/APR/12,/1988/

TABLET; ORAL-28
NORETHIN 1/35E-28
AB ROBERTS 0.035MG;1MG N71481 001
APR 12, 1988
/AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ /N71481/001/
/APR/12,/1988/

ETHYNODIOL DIACETATE; MESTRANOL

/TABLET;/ORAL-21/
/OVULEN-21/
/+//SEARLE/ /1MG;0.1MG/ /N16029/003/
@ SEARLE 1MG;0.1MG N16029 003

/TABLET;/ORAL-28/
/OVULEN-28/
/SEARLE/ /1MG;0.1MG/ /N16705/001/
@ SEARLE 1MG;0.1MG N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
>ADD > + MGI 50MG/ML N19545 001
>ADD > APR 20, 1987
>DLT > /P/AND/G/ /50MG/ML/ /N19545/001/
>DLT > /APR/20,/1987/

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/0.01%/	/N88047/001/ /DEC/16,/1982/	
/AT/		/0.025%/	/N88045/001/ /DEC/16,/1982/	
	@ PHARMADERM	0.01%	N88047 001 DEC 16, 1982	
	@	0.025%	N88045 001 DEC 16, 1982	

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/0.025%/	/N88046/001/ /DEC/16,/1982/
	@ PHARMADERM	0.025%	N88046 001 DEC 16, 1982

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

/AP/	/MARCHAR/	/50MG/ML/	/N87791/001/ /JAN/18,/1983/
	@ MARCHAR	50MG/ML	N87791 001 JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

	LILLY	EQ 10MG BASE	N18936 006 DEC 23, 1992

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HCL

AA	COPLEY	2.5MG/5ML	N81310 001 APR 29, 1993

PROLIXIN

AA	SQUIBB	2.5MG/5ML	N12145 003

>DLT>	/TABLET;/EXTENDED/RELEASE;/ORAL/			
>DLT>	/PERMITIL/			
>DLT>	/+//SCHERING/	/1MG/	/N12419/004/	

FLUPHENAZINE HYDROCHLORIDE

>DLT>	/TABLET;/EXTENDED/RELEASE;/ORAL/			
>DLT>	/PERMITIL/			
>ADD>	@ SCHERING	1MG		N12419 004

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AA/	/PIONEER/PHARMS/	/1MG/	/N88949/001/ /SEP/13,/1985/	
	@ PIONEER PHARMS	1MG	N88949 001 SEP 13, 1985	

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

>DLT>	/AB/	/PARKE/DAVIS/	/20MG/	/N18419/001/ /JAN/31,/1983/
>DLT>	/AB/		/40MG/	/N18419/002/ /JAN/31,/1983/
>DLT>	/AB/		/80MG/	/N18419/003/ /NOV/13,/1984/
>ADD>	@ WARNER CHILCOTT		20MG	N18419 001 JAN 31, 1983
>ADD>	@		40MG	N18419 002 JAN 31, 1983
>ADD>	@		80MG	N18419 003 NOV 13, 1984

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

	STERLING WINTHROP	287MG/ML	N20123 001 JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

AB	MYLAN	300MG	N73466 001 JAN 25, 1993
AB	PUREPAC	300MG	N72929 001 JAN 29, 1993

LOPID

AB	+ PARKE DAVIS	300MG	N18422 002

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

/AT/	/PHARMADERM/	/EQ 1MG BASE/GM/	/N62530/001/	
			/JUL/05,/1984/	
	@ PHARMADERM	EQ 1MG BASE/GM	N62530 001	
			JUL 05, 1984	

OINTMENT; OPHTHALMIC

> DLT >	/GENTAFAIR/			
> DLT > /AT/	/PHARMAFAIR/	/EQ 3MG BASE/GM/	/N62443/001/	
> DLT >			/MAY/26,/1983/	
> ADD >	@ PHARMAFAIR	EQ 3MG BASE/GM	N62443 001	
> ADD >			MAY 26, 1983	

GLIPIZIDE

TABLET; ORAL

GLUCOTROL

+ PFIZER	10MG		N17783 002
			MAY 08, 1984
	2.5MG		N17783 003
			MAY 11, 1993
	5MG		N17783 001
			MAY 08, 1984
/+//ROERIG/	/10MG/		/N17783/002/
			/MAY/08,/1984/
	/5MG/		/N17783/001/
			/MAY/08,/1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

/AP/	/LILLY/	/EQ 1MG BASE/VIAL/	/N12122/001/	
	LILLY	EQ 1MG BASE/VIAL	N12122 001	
/AP/	/QUAD/	/EQ 1MG BASE/VIAL/	/N71022/001/	
			/MAR/04,/1987/	
	@ QUAD	EQ 1MG BASE/VIAL	N71022 001	
			MAR 04, 1987	

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

/3/RHONE/POULENC/RORER//500MG/			/N09519/008/

GLYBURIDE

TABLET; ORAL

> DLT >	/GLUBATE/			
> DLT > /BX/	/HOECHST/ROUSSEL/	/1.5MG/		/N20055/001/
> DLT >				/APR/17,/1992/
> DLT > /BX/		/3MG/		/N20055/002/
> DLT >				/APR/17,/1992/
> ADD >	@ HOECHST ROUSSEL	1.5MG		N20055 001
> ADD >				APR 17, 1992
> ADD >	@	3MG		N20055 002
> ADD >				APR 17, 1992

GLYNASE

> DLT > /BX/	/UPJOHN/	/1.5MG/		/N20051/001/
> DLT >				/MAR/04,/1992/
> DLT > /BX/+/		/3MG/		/N20051/002/
> DLT >				/MAR/04,/1992/
> ADD >	+ UPJOHN	3MG		N20051 002
> ADD >				MAR 04, 1992
> ADD >		1.5MG		N20051 001
> ADD >				MAR 04, 1992

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

> ADD >	+ FERRING	0.8MG/VIAL	N19687 001
> ADD >			OCT 10, 1989
> ADD >	+	3.2MG/VIAL	N19687 002
> ADD >			OCT 10, 1989
> DLT >	/LUTREPULSE/PUMP/KIT/		
> DLT >	/FERRING/	/0.8MG/VIAL/	/N19687/001/
> DLT >			/OCT/10,/1989/
> DLT >		/3.2MG/VIAL/	/N19687/002/
> DLT >			/OCT/10,/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

> DLT > /AP/	/BEL/MAR/	/5,000 UNITS/VIAL/		/N17054/001/
> ADD > AP	@ BEL MAR	5,000 UNITS/VIAL		N17054 001
> DLT > /AP/		/10,000 UNITS/VIAL/		/N17054/002/
> ADD > AP	@	10,000 UNITS/VIAL		N17054 002

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL
GRISACTIN
/WYETH/AYERST/ /125MG/ /N50051/002/
@ WYETH AYERST 125MG N50051 002

HALOFANTRINE HYDROCHLORIDE

>DLT> /TABLET;ORAL/
>DLT> /HALFAN/
>DLT> /+//SMITHKLINE/BEECHAM/ /250MG/ /N20250/001/
>DLT>
>ADD> @ SMITHKLINE BEECHAM 250MG /JUL/24,/1992/
>ADD> N20250 001
JUL 24, 1992

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL
AA PHARM ASSOC EQ 2MG BASE/ML N73037 001
FEB 26, 1993

INJECTABLE; INJECTION
HALOPERIDOL
AP MARSAM EQ 5MG BASE/ML N72516 001
FEB 25, 1993
AP EQ 5MG BASE/ML N72517 001
FEB 25, 1993
/AP/ /SMITH/NEPHEW/SOLOPAK/EQ 5MG BASE/ML/ /N70801/001/
/DEC/14,/1987/
/AP/ /EQ 5MG BASE/ML/ /N70864/001/
/DEC/14,/1987/
AP SOLOPAK EQ 5MG BASE/ML N70801 001
DEC 14, 1987
AP EQ 5MG BASE/ML N70864 001
DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION
LIQUAEMIN SODIUM
>DLT>/AP/ /ORGANON/ /20,000 UNITS/ML/ /N00552/001/
>DLT>/AP/ /40,000 UNITS/ML/ /N00552/002/
>ADD> @ ORGANON 20,000 UNITS/ML N00552 001
>ADD> @ 40,000 UNITS/ML N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL
/TURGEX/
/XTTRIUM/ /3%/ /N18375/001/
@ XTTRIUM 3% N18375 001

EMULSION; TOPICAL
/HEXA-GERM/
/AT/ /HUNTINGTON/ /3%/ /N17411/001/
@ HUNTINGTON 3% N17411 001

PHISOHEX
>DLT>/AT/ /STERLING/ /3%/ /N08402/001/
>ADD> @ STERLING 3% N08402 001
/TURGEX/
/AT/ /XTTRIUM/ /3%/ /N19055/001/
/NOV/30,/1984/
@ XTTRIUM 3% N19055 001
NOV 30, 1984

/SOLUTION;TOPICAL/
/DIAL/
/AT/ /ARMOUR/DIAL/ /0.25%/ /N17421/002/
@ DIAL 0.25% N17421 002

/GERMA-MEDICA/
/HUNTINGTON/ /1%/ /N17412/001/
@ HUNTINGTON 1% N17412 001

/GERMA-MEDICA/MG/
/HUNTINGTON/ /0.25%/ /N17412/002/
@ HUNTINGTON 0.25% N17412 002

SPONGE; TOPICAL
/HEXASCRUB/
/AT/ /PROF/DSPLS/ /3%/ /N18363/001/
@ PROF DSPLS 3% N18363 001
>DLT> /PHISO-SCRUB/
>DLT>/AT/ /STERLING/ /3%/ /N17446/001/
>ADD> @ STERLING 3% N17446 001
>DLT> /SCRUBTEAM/SURGICAL/SPONGEBRUSH/
>DLT> /3M/ /330MG/ /N17413/001/
>ADD> @ 3M 330MG N17413 001

HEXAFLUORENIUM BROMIDE

/INJECTABLE;INJECTION/
/MYLAXEN/
/WALLACE/ /20MG/ML/ /N09789/003/
@ WALLACE 20MG/ML N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE

>DLT>		/LILLY/	/EQ 0.1MG BASE/ML/	/N00734 003/
>ADD>	@	LILLY	EQ 0.1MG BASE/ML	N00734 003
>DLT>			/EQ 0.2MG BASE/ML/	/N00734 002/
>ADD>	@		EQ 0.2MG BASE/ML	N00734 002
>DLT>			/EQ 1MG BASE/ML/	/N00734 001/
>ADD>	@		EQ 1MG BASE/ML	N00734 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

/TABLET;ORAL/
/SERPASIL-APRESOLINE/

	/+/	/CIBA/	/50MG;0.2MG/	/N09296 002/
			/25MG;0.1MG/	/N09296 004/
	@	CIBA	25MG;0.1MG	N09296 004
	@		50MG;0.2MG	N09296 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

>DLT>/AB/		/INWOOD/	/25MG/	/N84776 001/
>DLT>/AB/			/50MG/	/N84776 002/
>ADD>	@	INWOOD	25MG	N84776 001
>ADD>	@		50MG	N84776 002

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL
NORMOZIDE

>DLT>/AB/		/SCHERING/	/25MG;100MG/	/N19046 001/
				/APR 06, 1987/
>DLT>/AB/			/25MG;200MG/	/N19046 002/
				/APR 06, 1987/
>DLT>/AB/+/			/25MG;300MG/	/N19046 003/
				/APR 06, 1987/
>ADD>	+	SCHERING	25MG;300MG	N19046 003
				APR 06, 1987
>ADD>			25MG;100MG	N19046 001
				APR 06, 1987
>ADD>			25MG;200MG	N19046 002
				APR 06, 1987

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL
/TRANDATE HCT/

>DLT>		/GLAXO/	/25MG;100MG/	/N19174 001/
				/APR 10, 1987/
>DLT>/AB/			/25MG;200MG/	/N19174 002/
				/APR 10, 1987/
>DLT>/AB/			/25MG;300MG/	/N19174 003/
				/APR 10, 1987/
>ADD>	@	GLAXO	25MG;100MG	N19174 001
				APR 10, 1987
>ADD>	@		25MG;200MG	N19174 002
				APR 10, 1987
>ADD>	@		25MG;300MG	N19174 003
				APR 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
ZESTORETIC 20/12.5

/AB/		/IMPERIAL/CHEM/	/12.5MG;20MG/	/N19888 001/
				/SEP 20, 1990/
AB		ZENECA	12.5MG;20MG	N19888 001
				SEP 20, 1990

ZESTORETIC 20/25

/AB/		/IMPERIAL/CHEM/	/25MG;20MG/	/N19888 002/
				/JUL 20, 1989/
AB		ZENECA	25MG;20MG	N19888 002
				JUL 20, 1989

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT		BARRE	2.5%	N89682 001
				MAR 10, 1988
/AT/		/BIOCRAFT/	/0.5%/	/N80400 002/
/AT/			/1%/	/N80400 003/
/AT/			/2.5%/	/N80400 004/
	@	BIOCRAFT	0.5%	N80400 002
	@		1%	N80400 003
	@		2.5%	N80400 004
/AT/		/NASKA/	/2.5%/	/N89682 001/
				/MAR 10, 1988/
/AT/		/PHARMADERM/	/1%/	/N88845 001/
				/FEB 27, 1986/
	@	PHARMADERM	1%	N88845 001
				FEB 27, 1986

HYDROCORTISONE

LOTION; TOPICAL
ACTICORT

AT	BAKER NORTON	1%	N86535 001	
/AT/	/KEY/PHARMS/	/1%/	/N86535/001/	

OINTMENT; TOPICAL
HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001 MAY 28, 1993	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC
/NEOMYCIN SULFATE; POLYMYXIN B SULFATE E HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62617/001/ /SEP/18,/1985/	
	ə PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001 SEP 18, 1985	

SUSPENSION/DROPS; OPHTHALMIC
/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

>DLT> >DLT>	/AT/ /PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62623/001/ /SEP/24,/1985/	
>ADD> >ADD> >ADD>	ə PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001 SEP 24, 1985	

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

>DLT> /AP/	/BEL/MAR/	/25MG/ML/	/N83739/001/	
>DLT> /AP/		/50MG/ML/	/N83739/002/	
>ADD>	ə BEL MAR	25MG/ML	N83739 001	
>ADD>	ə	50MG/ML	N83739 002	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL
PRAMOSONE

>DLT>	/FERNDALE/	/0.5%;1%/	/N83213/002/	
>ADD>	ə FERNDALE	0.5%;1%	N83213 002	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
HYDROXOMIN

>DLT> /AP/	/BEL/MAR/	/1MG/ML/	/N84629/001/	
>ADD>	ə BEL MAR	1MG/ML	N84629 001	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	FUJISAWA	25MG/ML	N88184 001 MAR 31, 1983	
AP		50MG/ML	N88185 001 MAR 31, 1983	
/AP/	/LYPHOMED/	/25MG/ML/	/N88184/001/ /MAR/31,/1983/	
/AP/		/50MG/ML/	/N88185/001/ /MAR/31,/1983/	

SYRUP; ORAL
HYDROXYZINE HCL

AA	BARRE	10MG/5ML	N88785 001 FEB 03, 1988	
/AA/	/NASKA/	/10MG/5ML/	/N88785/001/ /FEB/03,/1988/	

TABLET; ORAL
HYDROXYZINE HCL

>DLT> /AB/	/CHELSEA/	/10MG/	/N86827/001/	
>DLT> /AB/		/25MG/	/N86829/001/	
>DLT> /AB/		/50MG/	/N86836/001/	
>ADD>	ə CHELSEA	10MG	N86827 001	
>ADD>	ə	25MG	N86829 001	
>ADD>	ə	50MG	N86836 001	

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AB	NORTON HN	400MG	N71145 001 SEP 23, 1986	
AB		600MG	N71146 001 SEP 23, 1986	
AB		800MG	N71769 001 MAY 08, 1987	

IBUPROFEN

IOTROLAN

IBUPROFEN

TABLET; ORAL
IBUPROFEN

/AB/	/PAR/	/300MG/	/N70328/001/ /AUG/06,/1985/
	∂ PAR	300MG	N70328 001 AUG 06, 1985
	/IFEN/		
/AB/	/LUCHEM/	/400MG/	/N71145/001/ /SEP/23,/1986/
/AB/		/600MG/	/N71146/001/ /SEP/23,/1986/
/AB/		/800MG/	/N71769/001/ /MAY/08,/1987/

IDOXURIDINE

>DLT>	/OINTMENT;/OPHTHALMIC/			
>DLT>	/STOXIL/			
>DLT>	/+//SMITHKLINE/BEECHAM/	/0.5%/	/N15868/001/
>ADD>	∂ SMITHKLINE BEECHAM	0.5%	N15868 001

SOLUTION/DROPS; OPHTHALMIC

>DLT>	/STOXIL/			
>DLT>/AT/	/SMITHKLINE/BEECHAM/	/0.1%/	/N13934/001/
>ADD>	∂ SMITHKLINE BEECHAM	0.1%	N13934 001

INDAPAMIDE

TABLET; ORAL
LOZOL

	RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
IODOHIPPURATE SODIUM I 131

>DLT>/AP/	/CIS/US/	/0.2MCI/ML/	/N17313/001/
>ADD> AP	SORIN	0.2MCI/ML	N17313 001

IOTROLAN

/INJECTABLE;/INTRATHECAL/
/OSMOVIST/

	/BERLEX/	/EQ/190MG/IODINE/ML/	/N19580/001/ /DEC/07,/1989/
		/EQ/240MG/IODINE/ML/	/N19580/002/ /DEC/07,/1989/
	∂ BERLEX	EQ 190MG IODINE/ML	N19580 001 DEC 07, 1989
	∂	EQ 240MG IODINE/ML	N19580 002 DEC 07, 1989

IRON DEXTRAN

INJECTABLE; INJECTION
INFED

BP +	SCHEIN PHARM	EQ 50MG IRON/ML	N17441 001
	/IRON/DEXTRAN/		
/BP/	/STERIS/	/EQ/50MG/IRON/ML/	/N17441/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

/AN/	/ASTRA/	/0.125%/	/N87936/001/ /NOV/15,/1982/
		/0.062%/	/N87937/001/ /NOV/15,/1982/
	∂ ASTRA	0.062%	N87937 001 NOV 15, 1982
	∂	0.125%	N87938 001 NOV 15, 1982
/AN/	/PARKE/DAVIS/	/1%/	/N85889/001/
		/0.5%/	/N85997/001/
	∂ PARKE DAVIS	0.5%	N85997 001
	∂	1%	N85889 001

ISOFLURANE

LIQUID; INHALATION
FORANE

AN +	ANAQUEST	99.9%	N17624 001
	ISOFLURANE		
AN	ABBOTT	99.9%	N74097 001 JAN 25, 1993

ISONIAZID

TABLET; ORAL

/AA/	/STANDARD/	/EVERYLIFE/	/300MG/	/N80126/002/	
	∂ EVERYLIFE		300MG	N80126 002	

ISOPROPAMIDE IODIDE

> DLT >	/TABLET;ORAL/				
> DLT >	/DARBID/				
> DLT >		/SMITHKLINE/BEECHAM/	/EQ 5MG BASE/	/N10744/001/	
> ADD >		∂ SMITHKLINE BEECHAM	EQ 5MG BASE	N10744 001	

ISOPROTERENOL HYDROCHLORIDE

TABLET; RECTAL, SUBLINGUAL

	ISUPREL				
> DLT >		/STERLING/	/15MG/	/N06328/002/	
> ADD >		∂ STERLING	15MG	N06328 002	

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE				
/AB/		/ICI/	/20MG/	/N86405/002/ AUG 21, 1990	
/AB/			/30MG/	/N88124/001/ AUG 21, 1990	
/AB/			/40MG/	/N88125/001/ AUG 21, 1990	
AB		ZENECA	20MG	N86405 002 AUG 21, 1990	
AB			30MG	N88124 001 AUG 21, 1990	
AB			40MG	N88125 001 AUG 21, 1990	

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO				
> ADD > AB	+	WYETH	20MG	N19091 001 DEC 30, 1991	
> ADD >					
> ADD >		MONOKET			
> ADD > BX		SCHWARZ PHARMA	20MG	N20215 001 JUN 30, 1993	
> ADD >					
> ADD >			10MG	N20215 002 JUN 30, 1993	
> ADD >					

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KLEBCIL				
/AP/		/SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/	
/AP/			/EQ 500MG BASE/2ML/	/N62170/002/	
/AP/			/EQ 1GM BASE/3ML/	/N62170/003/	
		∂ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001	
		∂	EQ 500MG BASE/2ML	N62170 002	
		∂	EQ 1GM BASE/3ML	N62170 003	

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	LEDERLE	25MG	N74014 001 JAN 29, 1993	
AB		50MG	N74014 002 JAN 29, 1993	
AB		75MG	N74014 003 JAN 29, 1993	

LACTULOSE

SOLUTION; ORAL

	CEPHULAC			
/AA/	/MERRELL/DOW/	/10GM/15ML/	/N17657/001/	
	ENULOSE			
/AA/	/BARRE/	/10GM/15ML/	/N71548/001/ AUG/15/1988/	
	EVALOSE			
AA	COPLEY	10GM/15ML	N73497 001 MAY 28, 1993	
	GENERLAC			
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71842/001/ SEP/27/1988/	
	LACTULOSE			
	/SOLVAY/	/10GM/15ML/	/N17906/001/	
	LAXILOSE			
AA	TECHNILAB	10GM/15ML	N73686 001 MAY 28, 1993	

SOLUTION; ORAL, RECTAL

	ACILAC			
AA	TECHNILAB	10GM/15ML	N73685 001 MAY 28, 1993	

LACTULOSE

SOLUTION; ORAL, RECTAL

	CEPHULAC			
AA	MERRELL DOW	10GM/15ML	N17657 001	
	ENULOSE			
AA	BARRE	10GM/15ML	N71548 001	
			AUG 15, 1988	
	GENERLAC			
AA	PHARM BASICS	10GM/15ML	N71842 001	
			SEP 27, 1988	
	HEPTALAC			
AA	COPLEY	10GM/15ML	N73504 001	
			MAY 28, 1993	
	LACTULOSE			
	∂ SOLVAY	10GM/15ML	N17906 001	
/AA/	/PORTALAC/ /SOLVAY/	/10GM/15ML/	/N72374/001/ /MAR/22,/1989/	
	∂ SOLVAY	10GM/15ML	N72374 001	
			MAR 22, 1989	

LEUCOVORIN CALCIUM

TABLET; ORAL

	LEUCOVORIN CALCIUM			
AB	LEDERLE	EQ 10MG BASE	N71962 001	
			NOV 19, 1987	
AB	+	EQ 15MG BASE	N71104 001	
			MAR 04, 1987	
AB	ROXANE	EQ 5MG BASE	N72733 001	
			FEB 22, 1993	
AB		EQ 10MG BASE	N72734 001	
			FEB 22, 1993	
AB		EQ 15MG BASE	N72735 001	
			FEB 22, 1993	
AB		EQ 25MG BASE	N72736 001	
			FEB 22, 1993	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON			
	+ TAP	1MG/0.2ML	N19010 001	
			APR 09, 1985	
		/1MG/0.2ML/	/N19010/001/ /APR/09,/1985/	
		5MG/ML	N20263 001	
			APR 16, 1993	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON DEPOT			
	+ TAP	3.75MG/VIAL	N20011 001	
			OCT 22, 1990	
	+	7.5MG/VIAL	N19732 001	
			JAN 26, 1989	
		/3.75MG/VIAL/	/N20011/001/ /OCT/22,/1990/	
		/7.5MG/VIAL/	/N19732/001/ /JAN/26,/1989/	
	LUPRON DEPOT-PED			
	+ TAP	3.75MG/VIAL&7.5MG/VIAL	N20263 003	
			APR 16, 1993	
	+	7.5MG/VIAL&7.5MG/VIAL	N20263 004	
			APR 16, 1993	
	+	7.5MG/VIAL	N20263 002	
			APR 16, 1993	

LIDOCAINE

	/SUPPOSITORY;/RECTAL/		
	/XYLOCAINE/		
	/ASTRA/	/100MG/	/N13077/001/
	∂ ASTRA	100MG	N13077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL			
>DLT<	/AP/ /BEL/MAR/	/1%/	/N80710/001/	
>DLT<	/AP/	/2%/	/N80760/001/	
>ADD<	∂ BEL MAR	1%	N80710 001	
>ADD<	∂	2%	N80760 001	
>DLT<	/AP/ /BRISTOL/	/1%/	/N80390/001/	
>DLT<	/AP/	/2%/	/N80390/002/	
	AP FUJISAWA	1%	N80404 002	
	AP	2%	N80404 003	
>ADD<	∂	1%	N80390 001	
>ADD<	∂	2%	N80390 002	
	/AP/ /LYPHOMED/	/1%/	/N80404/002/	
	/AP/	/1%/	/N86761/001/	
	/AP/	/2%/	/N80404/003/	
	/AP/	/2%/	/N86761/002/	
	∂ LYPHOMED	1%	N86761 001	
	∂	2%	N86761 002	

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
LIDOCAINE HCL

AT	COPLEY	2%	N81318 001 APR 29, 1993	

LIOTRIX (T4;T3)

TABLET; ORAL
THYROLAR-0.25

	FOREST LABS	0.0125MG;0.0031MG	N16807 001
	/RHONE/POULENC/RORER//0.0125MG;0.0031MG/		/N16807/001/

THYROLAR-0.5

	FOREST LABS	0.025MG;0.00625MG	N16807 005
	/RHONE/POULENC/RORER//0.025MG;0.00625MG/		/N16807/005/

THYROLAR-1

	FOREST LABS	0.05MG;0.0125MG	N16807 004
	/RHONE/POULENC/RORER//0.05MG;0.0125MG/		/N16807/004/

THYROLAR-2

	FOREST LABS	0.1MG;0.025MG	N16807 002
	/RHONE/POULENC/RORER//0.1MG;0.025MG/		/N16807/002/

THYROLAR-3

+	FOREST LABS	0.15MG;0.0375MG	N16807 003
/+/	/RHONE/POULENC/RORER//0.15MG;0.0375MG/		/N16807/003/

THYROLAR-5

	@ FOREST LABS	0.25MG;0.0625MG	N16807 006
	/@/RHONE/POULENC/RORER//0.25MG;0.0625MG/		/N16807/006/

LISINOPRIL

TABLET; ORAL
ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/	/N19777/001/ /MAY/19,/1988/	
/AB/		/10MG/	/N19777/002/ /MAY/19,/1988/	
/AB/		/20MG/	/N19777/003/ /MAY/19,/1988/	
/AB//+/		/40MG/	/N19777/004/ /MAY/19,/1988/	
AB	ZENECA	5MG	N19777 001 MAY 19, 1988	
AB		10MG	N19777 002 MAY 19, 1988	
AB		20MG	N19777 003 MAY 19, 1988	
AB	+	40MG	N19777 004 MAY 19, 1988	
		2.5MG	N19777 005 APR 29, 1993	

LITHIUM CARBONATE

TABLET; ORAL
/ESKALITH/

>DLT>				
>DLT>	/AB//+//SMITHKLINE/BEECHAM/	/300MG/		/N17971/001/
>ADD>	@ SMITHKLINE BEECHAM	300MG		N17971 001

LORATADINE

TABLET; ORAL
CLARITIN

+	SCHERING	10MG	N19658 001 APR 12, 1993

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	HICKAM	EQ 85MG BASE/GM	N16763 001
	/STERLING/	/EQ/85MG/BASE/GM/	/N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE

	FUJISAWA	EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987
	/LYPHOMED/	/EQ/0.1MG/MANGANESE/ML/	/N19228/001/ /MAY/05,/1987/

MASOPROCOL

CREAM; TOPICAL
ACTINEX

>ADD>	+ BLOCK DRUG	10%		N19940 001 SEP 04, 1992
>ADD>				
>DLT>	/+//CHEMEX/	/10%/		/N19940/001/ /SEP/04,/1992/
>DLT>				

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/
/SYNKAYVITE/

	/ROCHE/	/5MG/ML/	/N03718/004/
		/10MG/ML/	/N03718/006/
		/37.5MG/ML/	/N03718/008/

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/
/SYNKAYVITE/
ə ROCHE 5MG/ML N03718 004
ə 10MG/ML N03718 006
ə 37.5MG/ML N03718 008

/TABLET;/ORAL/
/SYNKAYVITE/
/ROCHE/ /5MG/ /N03718/010/
ə ROCHE 5MG N03718 010

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
> DLT >/AA/ /LEE/LABS/ /400MG/ /N89538/001/
> DLT > /NOV/25,/1987/
> ADD > ə LEE LABS 400MG N89538 001
> ADD > NOV 25, 1987

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA
+ MARION MERRELL DOW 250MG N20049 001
MAY 10, 1993

MESTRANOL; NORETHINDRONE

/TABLET;/ORAL-20/
/NORINYL/
/SYNTEX/ /0.1MG;2MG/ /N13625/004/
ə SYNTEX 0.1MG;2MG N13625 004

TABLET; ORAL-21
NORETHIN 1/50M-21
AB ROBERTS 0.05MG;1MG N71539 001
APR 12, 1988
/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/ /N71539/001/
/APR/12,/1988/

TABLET; ORAL-28
NORETHIN 1/50M-28
AB ROBERTS 0.05MG;1MG N71540 001
APR 12, 1988

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28
NORETHIN 1/50M-28
/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/ /N71540/001/
/APR/12,/1988/

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL/
/ENOVID/
/+//SEARLE/ /0.15MG;9.85MG/ /N10976/005/
/0.075MG;5MG/ /N10976/008/
ə SEARLE 0.075MG;5MG N10976 008
ə 0.15MG;9.85MG N10976 005

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE
AP FUJISAWA EQ 10MG BASE/ML N80431 001
AP EQ 10MG BASE/ML N80722 001
/AP/ /LYPHOMED/ /EQ 10MG BASE/ML/ /N80431/001/
/AP/ /EQ 10MG BASE/ML/ /N80722/001/

METHADONE HYDROCHLORIDE

TABLET; ORAL
METHADOSE
AA MALLINCKRODT 5MG N40050 001
APR 15, 1993
AA 10MG N40050 002
APR 15, 1993

TABLET, DISPERSIBLE; ORAL
METHADONE HCL
AA LILLY 40MG N17058 001
METHADOSE
AA MALLINCKRODT 40MG N74184 001
APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
/METHAMPEX/
/AA/ /LEMMON/ /10MG/ /N83889/001/
ə LEMMON 10MG N83889 001

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE HCL

/AA/	/LEMMON/	/5MG/	/N86359/001/	
	@ LEMMON	5MG	N86359 001	
/AA/	/REXAR/	/10MG/	/N84931/002/	
	REXAR	10MG	N84931 002	

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

>ADD>				
>ADD> AB	COPLEY	25MG	N40001 001	
>ADD>			JUN 30, 1993	
>ADD> AB		50MG	N40001 002	
>ADD>			JUN 30, 1993	
>ADD> AB	GENEVA	25MG	N40036 001	
>ADD>			JUN 30, 1993	
>ADD> AB		50MG	N40036 002	
>ADD>			JUN 30, 1993	

NEPTAZANE

>ADD> AB	LEDERLE	25MG	N11721 002	
>ADD>			NOV 25, 1991	
>ADD> AB +		50MG	N11721 001	

METHOCARBAMOL

TABLET; ORAL

/DELAXIN/

/AA/	/FERNDALE/	/500MG/	/N85454/001/	
	@ FERNDALE	500MG	N85454 001	

METHOCARBAMOL

AA	NYLOS TRADING	750MG	N85033 001	
/AA/	/PIONEER PHARMS/	/500MG/	/N86731/001/	
/AA/		/750MG/	/DEC/13,/1985/	
	@ PIONEER PHARMS	500MG	/N89082/001/	
	@	750MG	/DEC/13,/1985/	
/AA/	/TABLICAPS/	/750MG/	N88731 001	
			DEC 13, 1985	
			N89082 001	
			DEC 13, 1985	
			/N85033/001/	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

>DLT>/AP/	/AKORN/	/EQ 25MG BASE/ML/	/N88648/001/	
>DLT>			/MAY/09,/1986/	
/AP/	/LYPHOMED/	/EQ 25MG BASE/ML/	/N89263/001/	
	@ LYPHOMED	EQ 25MG BASE/ML	/JUN/13,/1986/	
>ADD> AP	NORBROOK	EQ 25MG BASE/ML	N89263 001	
>ADD>			JUN 13, 1986	
			N88648 001	
			MAY 09, 1986	

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

/AP/	/LYPHOMED/	/50MG/ML/	/N70652/001/	
	@ LYPHOMED	50MG/ML	/JUN/03,/1986/	
			N70652 001	
			JUN 03, 1986	

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

/AB/	/CHELSEA/	/4MG/	/N86161/001/	
B*	CHELSEA	4MG	/FEB/09,/1982/	
			N86161 001	
			FEB 09, 1982	

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

/M-PREDROL/

>DLT>			/N86666/001/	
>DLT> /BP/	/BEL/MAR/	/40MG/ML/	/N87135/001/	
>DLT> /BP/		/80MG/ML/	N86666 001	
>ADD>	@ BEL MAR	40MG/ML	N87135 001	
>ADD>	@	80MG/ML		

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N89143/001/	/MAR/28,/1986/
/AP/		/EQ 125MG BASE/VIAL/	/N89144/001/	/MAR/28,/1986/
/AP/		/EQ 500MG BASE/VIAL/	/N89187/001/	/MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N89189/001/	/MAR/28,/1986/
	@ LYPHOMED	EQ 40MG BASE/VIAL	N89143 001	MAR 28, 1986
	@	EQ 125MG BASE/VIAL	N89144 001	MAR 28, 1986
	@	EQ 500MG BASE/VIAL	N89187 001	MAR 28, 1986
	@	EQ 1GM BASE/VIAL	N89189 001	MAR 28, 1986

METHYLTESTOSTERONE

CAPSULE; ORAL

	/METHYLTESTOSTERONE/			
/BP/	/HEATHER/	/10MG/	/N84967/001/	
	@ HEATHER	10MG	N84967 001	

TESTRED

>_DLT_> /BP/	/ICN/	/10MG/	/N83976/001/	
>_ADD_> BP +	ICN	10MG	N83976 001	

METHYPRYLON

/CAPSULE;ORAL/				
/NOLUDAR/				
/ROCHE/		/300MG/	/N09660/008/	
@ ROCHE		300MG	N09660 008	
/TABLET;ORAL/				
/NOLUDAR/				
/ROCHE/		/200MG/	/N09660/004/	
@ ROCHE		200MG	N09660 004	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

>_DLT_>/AP/	/AKORN/	/EQ 10MG BASE/2ML/	/N70892/001/	/AUG/26,/1988/	
>_DLT_					
>_DLT_>/AP/	/FUJISAWA/	/EQ 10MG BASE/2ML/	/N70293/001/	/JAN/24,/1986/	
>_DLT_					
>_ADD_	@ FUJISAWA	EQ 10MG BASE/2ML	N70293 001	JAN 24, 1986	
>_ADD_					
>_ADD_	@ NORBROOK	EQ 10MG BASE/2ML	N70892 001	AUG 26, 1988	
>_ADD_					

SOLUTION; ORAL

METOCLOPRAMIDE HCL

>_ADD_> AA	LEMMON	EQ 5MG BASE/5ML	N71315 001	JUN 30, 1993
>_ADD_				
>_ADD_> AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993
>_ADD_				

TABLET; ORAL

METOCLOPRAMIDE HCL

>_ADD_> AB	BIOCRAFT	EQ 5MG BASE	N72801 001	JUN 15, 1993
>_ADD_				
AB	MUTUAL PHARM	EQ 10MG BASE	N71536 001	APR 28, 1993
/AB/	/PAR/	/EQ 10MG BASE/	/N70342/001/	/MAR/25,/1986/
	@ PAR	EQ 10MG BASE	N70342 001	MAR 25, 1986

METRONIDAZOLE

TABLET; ORAL

	/SATRIC/			
/AB/	/SAVAGE/	/250MG/	/N70029/001/	/MAR/19,/1985/
/AB/		/500MG/	/N70731/001/	/JUN/08,/1987/
	@ SAVAGE	250MG	N70029 001	MAR 19, 1985
	@	500MG	N70731 001	JUN 08, 1987

MICONAZOLE NITRATE

/CREAM;VAGINAL/			
/MONISTAT 7/			
/JOHNSON PW/	/2%/		/N17456/001/

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
+ JOHNSON RW — 2%;200MG — N18888 002 OCT 17, 1988

/LOTION;/TOPICAL/
/MONISTAT-DERM/
/+//JOHNSON/RW/ — /2%/
ə JOHNSON RW — 2% — /N17739/001/ N17739 001

/SUPPOSITORY;/VAGINAL/
/MONISTAT/7/
/JOHNSON/RW/ — /100MG/ — /N18520/001/ /MAR/15,/1982/

MILRINONE LACTATE

> ADD > INJECTABLE; INJECTION
> ADD > MILRINONE LACTATE
> ADD > + STERLING — EQ 1MG BASE/ML — N19436 001 DEC 31, 1987
> ADD > /S/ — /EQ/1MG/BASE/ML/ — /N19436/001/ /DEC/31,/1987/
> DLT >
> DLT >

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/ — /200MG/ — /N19753/001/ /JUN/19,/1990/
/250MG/ — /N19753/002/ /JUN/19,/1990/
/300MG/ — /N19753/003/ /JUN/19,/1990/
ROBERTS — 200MG — N19753 001 JUN 19, 1990
250MG — N19753 002 JUN 19, 1990
300MG — N19753 003 JUN 19, 1990

NABILONE

/CAPSULE;/ORAL/
/CESAMET/
/+//LILLY/ — /1MG/ — /N18677/001/ /DEC/26,/1985/
ə LILLY — 1MG — N18677 001 DEC 26, 1985

NAFCILLIN SODIUM

/POWDER/FOR/RECONSTITUTION;/ORAL/
/UNIPEN/
/+//WYETH/AYERST/ — /EQ/250MG/BASE/5ML/ — /N50199/001/
ə WYETH AYERST — EQ 250MG BASE/5ML — N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE
ABBOTT — 1.5MG/ML — N20200 001 MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
/AP/ /LYPHOMED/ — /0.02MG/ML/ — /N70661/001/ /NOV/17,/1986/
ə LYPHOMED — 0.02MG/ML — N70661 001 NOV 17, 1986

NARCAN
/AP/ /DUPONT/ — /0.4MG/ML/ — /N71083/001/ /JUL/28,/1988/
/AP/ — /1MG/ML/ — /N71084/001/ /JUL/28,/1988/
/AP/ — /1MG/ML/ — /N71311/001/ /JUL/28,/1988/
ə DUPONT — 0.4MG/ML — N71083 001 JUL 28, 1988
ə — 1MG/ML — N71084 001 JUL 28, 1988
ə — 1MG/ML — N71311 001 JUL 28, 1988

NANDROLONE DECANOATE

NITROFURANTOIN

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AO/	/LYPHOMED/	/100MG/ML/	/N88290/001/ /OCT/03,/1983/	
/AO/		/200MG/ML/	/N88317/001/ /OCT/14,/1983/	
	∂ LYPHOMED	100MG/ML	N88290 001 OCT 03, 1983	
	∂	200MG/ML	N88317 001 OCT 14, 1983	

NIACIN

/CAPSULE;/ORAL/

/NAMPOCAP/

/WALLACE/	/500MG/	/N11073/003/	
∂ WALLACE	500MG	N11073 003	

TABLET; ORAL

NIACIN

/AA/	/ZENITH/	/500MG/	/N83180/001/	
	∂ ZENITH	500MG	N83180 001	

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

BC	MILES	30MG	N20198 001 APR 21, 1993	
BC		60MG	N20198 002 APR 21, 1993	
BC		90MG	N20198 003 APR 21, 1993	

PROCARDIA XL

BC +	PFIZER	30MG	N19684 001 SEP 06, 1989	
BC +		60MG	N19684 002 SEP 06, 1989	
BC +		90MG	N19684 003 SEP 06, 1989	
/+/		/30MG/	/N19684/001/ /SEP/06,/1989/	
/+/		/60MG/	/N19684/002/ /SEP/06,/1989/	
/+/		/90MG/	/N19684/003/ /SEP/06,/1989/	

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

/AB/	/ZENITH/	/50MG/	/N80078/002/	
/AB/		/100MG/	/N80078/001/	
	∂ ZENITH	50MG	N80078 002	
	∂	100MG	N80078 001	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

AB	ZENITH	50MG	N73671 001 JAN 28, 1993
AB		100MG	N73652 001 JAN 28, 1993

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62949 001 JUN 13, 1988
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62949/001/ /JUN/13,/1988/
AT	TARO	100,000 UNITS/GM	N64022 001 JAN 29, 1993

OINTMENT; TOPICAL

NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62840 001 NOV 13, 1987
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62840/001/ /NOV/13,/1987/

POWDER; ORAL

/BACITRACIN 100/

/AA/	/BARLAN/	/100%/	/N62489/001/ /APR/27,/1988/	
	∂ BARLAN	100%	N62489 001 APR 27, 1988	

SUSPENSION; ORAL

MYCOSTATIN

> ADD >	AA	APOTHECON	100,000 UNITS/ML	N61533 001
> DLT >	/AA/	/BRISTOL/MYERS/SQUIBB/	/100,000 UNITS/ML/	/N61533/001/

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA	BARRE	100,000 UNITS/ML	N62571 001 OCT 29, 1985
/AA/	/NASKA/	/100,000 UNITS/ML/	/N62571/001/ /OCT/29,/1985/
/AA/	/PHARMADERM/	/100,000 UNITS/ML/	/N62518/001/ /JUL/06,/1984/
	@ PHARMADERM	100,000 UNITS/ML	N62518 001 JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
/AT/	/NASKA/	/100,000 UNITS/GM;0.1%/	/N63010/001/ /DEC/20,/1988/

NYSTATIN-TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62596/001/ /OCT/08,/1985/
	@ PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001 OCT 08, 1985

OINTMENT; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	TARO	100,000 UNITS/GM;0.1%	N63305 001 MAR 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN
/SANDOZ/

	/EQ/50UGM/BASE/ML/	/N19667/001/ /OCT/21,/1988/
SANDOZ	EQ 0.05MG BASE/ML	N19667 001 OCT 21, 1988
	/EQ/100UGM/BASE/ML/	/N19667/002/ /OCT/21,/1988/
	EQ 0.1MG BASE/ML	N19667 002 OCT 21, 1988
	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
	/EQ/500UGM/BASE/ML/	/N19667/003/ /OCT/21,/1988/
	EQ 0.5MG BASE/ML	N19667 003 OCT 21, 1988
	EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

OXPRENOLOL HYDROCHLORIDE

/CAPSULE;ORAL/
/TRASICOR/
/+//CIBA/

	/160MG/	/N18166/004/ /DEC/28,/1983/
	/20MG/	/N18166/001/ /DEC/28,/1983/
	/40MG/	/N18166/002/ /DEC/28,/1983/
	/80MG/	/N18166/003/ /DEC/28,/1983/
@ CIBA	20MG	N18166 001 DEC 28, 1983
@	40MG	N18166 002 DEC 28, 1983
@	80MG	N18166 003 DEC 28, 1983
@	160MG	N18166 004 DEC 28, 1983

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

+ PHARM CIBA GEIGY	60MG/VIAL	N20036 003 MAY 06, 1993
+	90MG/VIAL	N20036 004 MAY 06, 1993

PARAMETHASONE ACETATE

TABLET; ORAL

	HALDRONE			
>DLT>	/#//LILLY/	/2MG/	/N12772/006/	
>DLT>		/1MG/	/N12772/005/	
>ADD>	@ LILLY	1MG	N12772 005	
>ADD>	@	2MG	N12772 006	

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

	PAXIL			
>DLT>	/#//SMITHKLINE/BEECHAM/	/EQ/10MG/BASE/	/N20031/001/ /DEC/29,/1992/	
>DLT>	/#/	/EQ/30MG/BASE/	/N20031/004/ /DEC/29,/1992/	
>ADD>	@ SMITHKLINE BEECHAM	EQ 10MG BASE	N20031 001 DEC 29, 1992	
>DLT>		/EQ/40MG/BASE/	/N20031/005/ /DEC/29,/1992/	
>ADD>	@	EQ 40MG BASE	N20031 005 DEC 29, 1992	
>ADD>	@	EQ 50MG BASE	N20031 004 DEC 29, 1992	

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A			
/#//WYETH/AYERST/	/300,000/UNITS/ML/	/N50131/001/	
+ WYETH AYERST	300,000 UNITS/ML	N50141 003	
@	300,000 UNITS/ML	N50131 001	
	/300,000/UNITS/ML/	/N50141/003/	

/TABLET;/ORAL/

/BICILLIN/		
/#//WYETH/AYERST/	/200,000/UNITS/	/N50128/001/
@ WYETH AYERST	200,000 UNITS	N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	PENICILLIN			
/AA/	/BIOCRAFT/	/200,000 UNITS/5ML/	/N60307/002/	
	BIOCRAFT	200,000 UNITS/5ML	N60307 002	
	/PENTIDS,1200/			
/AA/	/SQUIBB/	/200,000 UNITS/5ML/	/N62149/001/	
	@ APOTHECON	200,000 UNITS/5ML	N62149 001	

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/PENTIDS,1400/			
/AA/	/SQUIBB/	/400,000 UNITS/5ML/	/N62149/002/	
	@ APOTHECON	400,000 UNITS/5ML	N62149 002	

TABLET; ORAL

	PENICILLIN G POTASSIUM			
	@ APOTHECON	250,000 UNITS	N60392 003	
/AB/	/SQUIBB/	/250,000 UNITS/	/N60392/003/	
	/PENTIDS,1200/			
/AB/	/SQUIBB/	/200,000 UNITS/	/N62155/001/	
	@ APOTHECON	200,000 UNITS	N62155 001	
	/PENTIDS,1250/			
/AB/	/SQUIBB/	/250,000 UNITS/	/N62155/002/	
	@ APOTHECON	250,000 UNITS	N62155 002	
	/PENTIDS,1400/			
/AB/	/SQUIBB/	/400,000 UNITS/	/N60392/004/	
/AB/		/400,000 UNITS/	/N62155/003/	
	@ APOTHECON	400,000 UNITS	N60392 004	
	@	400,000 UNITS	N62155 003	
	/PENTIDS,1800/			
/AB/	/SQUIBB/	/800,000 UNITS/	/N60392/005/	
/AB/		/800,000 UNITS/	/N62155/004/	
	@ APOTHECON	800,000 UNITS	N60392 005	
	@	800,000 UNITS	N62155 004	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

/DURACILLIN A.S./			
/AP/ /LILLY/	/300,000 UNITS/ML/	/N60093/001/	
@ LILLY	300,000 UNITS/ML	N60093 001	

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/VEETIDS,1125/			
/AA/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N61206/001/	
/AA/		/EQ 125MG BASE/5ML/	/N62153/001/	
	@ APOTHECON	EQ 125MG BASE/5ML	N61206 001	
	@	EQ 125MG BASE/5ML	N62153 001	
	/VEETIDS,1250/			
/AA/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N61206/002/	
/AA/		/EQ 250MG BASE/5ML/	/N62153/002/	
	@ APOTHECON	EQ 250MG BASE/5ML	N61206 002	
	@	EQ 250MG BASE/5ML	N62153 002	

PENICILLIN V POTASSIUM

TABLET; ORAL

	VEETIDS '250'			
AB	SQUIBB	EQ 250MG BASE	N61164 001	
AB		EQ 250MG BASE	N62156 002	
	ə APOTHECON	EQ 250MG BASE		
	ə			
	VEETIDS '500'			
AB	SQUIBB	EQ 500MG BASE	N61164 002	
AB		EQ 500MG BASE	N62156 001	
	ə APOTHECON	EQ 500MG BASE		
	ə			

PERMETHRIN

> DLT >	LOTION;TOPICAL			
> DLT >	NIX			
> DLT >	A	+/BURROUGHS WELLCOME	1%	N19435 001 MAR 31, 1986
> DLT >				
> ADD >		ə BURROUGHS WELLCOME	1%	
> ADD >				

PERPHENAZINE

> DLT >	TABLET;EXTENDED RELEASE;ORAL			
> DLT >	TRILAFON			
> DLT >	+/SCHERING	8MG	N11361 002	
> ADD >	ə SCHERING	8MG		

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

	ADPHEN			
AA	FERNDALE	35MG	N83655 001	
	ə FERNDALE	35MG		
	METRA			
AA	FOREST PHARMS	35MG	N83754 001	
	ə FOREST PHARMS	35MG		
	PHENDIMETRAZINE TARTRATE			
AA	ANABOLICS	35MG	N86020 001	
	ə ANABOLICS	35MG		
AA	FERNDALE	35MG	N86834 001 SEP 15, 1983	
	ə FERNDALE	35MG		

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	ADIPEX-P			
AA	LEMMON	30MG	N86911 001	
> DLT >	ONESTIN-30			
> DLT > AA	FERNDALE	30MG	N87144 001	
> ADD >	ə FERNDALE	30MG		
	PHENTERMINE HCL			
	ə LEMMON	30MG	N86911 001	
AA	ZENITH	30MG	N86329 001	
	ə ZENITH	30MG		

PHENYLBUTAZONE

CAPSULE; ORAL

	PHENYLBUTAZONE			
AB	CHELSEA	100MG	N87756 001 DEC 17, 1982	
B*	CHELSEA	100MG		

PHYTONADIONE

INJECTABLE; INJECTION

	AQUAMEPHYTON			
BP	MSD	10MG/ML	N12223 001	
BP +	MSD	10MG/ML		
	KONAKION			
BP	ROCHE	10MG/ML	N11745 003	
BP	ROCHE	10MG/ML		

PINDOLOL

TABLET; ORAL

	PINDOLOL			
AB	GENEVA	5MG	N73608 001 MAR 29, 1993	
AB		10MG	N73609 001 MAR 29, 1993	
AB	PUREPAC	5MG	N74125 001 APR 28, 1993	
AB		10MG	N74125 002 APR 28, 1993	
AB	ZENITH	5MG	N73687 001 FEB 26, 1993	
AB		10MG	N73687 002 FEB 26, 1993	

PIROXICAM

CAPSULE; ORAL

		PIROXICAM			
> ADD >	AB	MEPHA AG	10MG	N74116 001	JUN 15, 1993
> ADD >					
> ADD >	AB		20MG	N74118 001	JUN 15, 1993
> ADD >					
	AB	MUTUAL PHARM	10MG	N73535 001	MAR 12, 1993
	AB		20MG	N73536 001	MAR 12, 1993
	AB	ROXANE	10MG	N73651 001	FEB 26, 1993
	AB		20MG	N73651 002	FEB 26, 1993

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		K-LEASE			
/AB/	/ADRIA/		/8MEQ/	/N73398/001/	/JAN/28,/1992/
/AB/			/10 MEQ/	/N72427/001/	/MAR/28,/1990/
AB	SAVAGE		8MEQ	N73398 001	JAN 28, 1992
AB			10 MEQ	N72427 001	MAR 28, 1990

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE			
AP		FUJISAWA	2MEQ/ML	N84290 001	
AP			2MEQ/ML	N87787 001	APR 20, 1982
/AP/	/LUITPOLD/		/2MEQ/ML/	/N80221/001/	
/AP/			/2MEQ/ML/	/N80736/001/	
	ə LUITPOLD		2MEQ/ML	N80221 001	
	ə		2MEQ/ML	N80736 001	
/AP/	/LYPHOMED/		/2MEQ/ML/	/N84290/001/	
/AP/			/2MEQ/ML/	/N87787/001/	/APR/20,/1982/

TABLET, EXTENDED RELEASE; ORAL

		K+8			
AB		ALRA	8MEQ	N70998 001	JAN 25, 1993
		KAON CL			
		/ADRIA/	/6.7MEQ/	/N17046/001/	
		SAVAGE	6.7MEQ	N17046 001	

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		KAON CL-10			
/BC/	/ADRIA/		/10MEQ/	/N17046/002/	
BC		SAVAGE	10MEQ	N17046 002	

POTASSIUM CITRATE

/POWDER/FOR/RECONSTITUTION;/ORAL/

/POTASSIUM/CITRATE/				
/+//UNIV/TX/		/20MEQ/PACKET/	/N19647/001/	/OCT/13,/1988/
		/10MEQ/PACKET/	/N19647/002/	/OCT/13,/1988/
ə UNIV TX		10MEQ/PACKET	N19647 002	OCT 13, 1988
ə		20MEQ/PACKET	N19647 001	OCT 13, 1988

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE				
/+//UNIV/TX/		/5MEQ/	/N19071/001/	/AUG/30,/1985/
+ UNIV TX		10MEQ	N19071 002	AUG 31, 1992
		5MEQ	N19071 001	AUG 30, 1985

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL				
/+//BRISTOL/MYERS/SQUIBB/20MG/			/N19898/003/	/OCT/31,/1991/
+ BRISTOL MYERS SQUIBB	40MG		N19898 004	MAR 22, 1993
	20MG		N19898 003	OCT 31, 1991

PRAZEPAM

/TABLET;/ORAL/

/CENTRAX/				
/+//PARKE/DAVIS/		/10MG/	/N17415/001/	
ə PARKE DAVIS		10MG	N17415 001	

PREDNICARBATE

OINTMENT; TOPICAL

> DLT >	/DERMATOP/				
> DLT >	/HOECHST/ROUSSEL/	/0.1%/	/N19568/001/		
> DLT >			/SEP/23,/1991/		
> ADD >	@ HOECHST ROUSSEL	0.1%	N19568 001		
> ADD >			SEP 23, 1991		

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001		
			MAY 27, 1993		

VASOCIDIN

AT	IOLAB	EQ 0.23% PHOSPHATE;10%	N18988 001		
			AUG 26, 1988		

PREDNISONE

TABLET; ORAL

DELTASONE

AB	UPJOHN	2.5MG	N09986 005		
/BX/		/2.5MG/	/N09986/005/		

PREDNISONE

/AB/	/HEATHER/	/10MG/	/N84341/001/		
/AB/		/20MG/	/N85543/001/		
/AB/		/50MG/	/N86946/001/		
	@ HEATHER	10MG	N84341 001		
	@	20MG	N85543 001		
	@	50MG	N86946 001		
/BX/	/KV/	/5MG/	/N84236/001/		
	@ KV	5MG	N84236 001		
BX	NYLOS TRADING	5MG	N85115 001		
/BX/	/TABLICAPS/	/5MG/	/N85115/001/		

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/AP/	/LYPHOMED/	/100MG/ML/	/N89415/001/		
			/NOV/17,/1986/		
/AP/		/500MG/ML/	/N89416/001/		
			/NOV/17,/1986/		
	@ LYPHOMED	100MG/ML	N89415 001		
			NOV 17, 1986		
	@	500MG/ML	N89416 001		
			NOV 17, 1986		

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

> DLT >	/AP/ /BEL/MAR/	/1%/	/N80711/001/		
> DLT >	/AP/	/2%/	/N80756/001/		
> ADD >	@ BEL MAR	1%	N80711 001		
> ADD >	@	2%	N80756 001		

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

> DLT >	/BURROUGHS/WELLCOME/	/2MG/	/N09818/005/		
> ADD >	@ BURROUGHS WELLCOME	2MG	N09818 005		

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

/BR/	/ALCON/	/25MG/	/N84901/001/		
/BR/		/50MG/	/N84902/001/		
BR	POLYMEDICA	25MG	N84901 001		
BR		50MG	N84902 001		

TABLET; ORAL

PROMETHAZINE HCL

/BP/	/BOLAR/	/25MG/	/N83204/001/		
	@ BOLAR	25MG	N83204 001		
/BP/	/ZENITH/	/50MG/	/N83613/001/		
	@ ZENITH	50MG	N83613 001		

PROPRANOLOL HYDROCHLORIDE

/SUSPENSION;/ORAL/

/INDERAL/

	/WYETH/AYERST/	/10MG/ML/	/N19536/001/		
			/DEC/12,/1986/		
	@ WYETH AYERST	10MG/ML	N19536 001		
			DEC 12, 1986		

PROPYLIODONE

> DLT >	/SUSPENSION;/INTRATRACHEAL/				
> DLT >	/DIONOSIL/OILY/				
> DLT >	/GLAXO/	/60%/	/N09309/002/		
> ADD >	@ GLAXO	60%	N09309 002		

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/	/QUAD/	/10MG/ML/	/N89306/001/ /MAY/30,/1986/	
	@ QUAD	10MG/ML	N89306 001 MAY 30, 1986	

PYRANTEL PAMOATE

/SUSPENSION;/ORAL/
/ANTIMINTH/
/+//ROERIG/ /EQ/250MG/BASE/5ML/ /N16883/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

/AP/	/ICN/	/5MG/ML/	/N09830/001/
AP	ROCHE	5MG/ML	N09830 001

SYRUP; ORAL
MESTINON

	/ICN/	/60MG/5ML/	/N15193/001/
	ROCHE	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

	/+//ICN/	/60MG/	/N09829/002/
	+ ROCHE	60MG	N09829 002

TABLET, EXTENDED RELEASE; ORAL
MESTINON

	/+//ICN/	/180MG/	/N11665/001/
	+ ROCHE	180MG	N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

>DLT >/AP/	/BEL/MAR/	/100MG/ML/	/N80761/001/	
>ADD >	@ BEL MAR	100MG/ML	N80761 001	
AP	FUJISAWA	100MG/ML	N80618 001	
/AP/	/LYPHOMED/	/100MG/ML/	/N80618/001/	

QUAZEPAM

TABLET; ORAL
DORAL

/+//BAKER/NORTON/	/15MG/	/N18708/001/ /DEC/27,/1985/	
	/7.5MG/	/N18708/003/ /FEB/26,/1987/	
+ WALLACE	15MG	N18708 001 DEC 27, 1985	
	7.5MG	N18708 003 FEB 26, 1987	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
/DURAQUIN/

/PARKE/DAVIS/	/330MG/	/N17917/001/	
@ WARNER CHILCOTT	330MG	N17917 001	

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

/AB/	/PARKE/DAVIS/	/200MG/	/N83879/001/	
>ADD >	@ WARNER CHILCOTT	200MG	N83879 001	

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
/NAQUIVAL/

>DLT >			
>DLT >	/BP/+//SCHERING/	/0.1MG;4MG/	/N12265/003/
>ADD >	@ SCHERING	0.1MG;4MG	N12265 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

/AP/	/QUAD/	/10MG/ML/	/N70700/001/ /OCT/06,/1986/
	@ QUAD	10MG/ML	N70700 001 OCT 06, 1986

SERACTIDE ACETATE

/INJECTABLE;/INJECTION/
/ACTHAR/GEL-SYNTHETIC/
/ARMOUR/ /40/UNITS/ML/ /N17861/001/
/80/UNITS/ML/ /N17861/002/
@ ARMOUR 40 UNITS/ML N17861 001
@ 80 UNITS/ML N17861 002

SILVER SULFADIAZINE

>DLT> /DRESSING;/TOPICAL/
>DLT> /SILDIMAC/
>ADD> @ BIOPLASTY 1% N19608 001
>ADD> NOV 30, 1989

>DLT> /SILDIMAC/
>DLT> /ENDAY/ /1%/ /N19608/001/
>DLT> /NOV/30,/1989/

SODIUM BICARBONATE

>DLT> /INJECTABLE;/INJECTION/
>DLT> /SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/
>DLT> /ABBOTT/ /0.9MEQ/ML/ /N19443/001/
>DLT> /JUN/03,/1986/
>DLT> /1MEQ/ML/ /N19443/002/
>DLT> /JUN/03,/1986/
>ADD> @ ABBOTT 0.9MEQ/ML N19443 001
>ADD> JUN 03, 1986
>ADD> @ 1MEQ/ML N19443 002
>ADD> JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP FUJISAWA 9MG/ML N88911 001
FEB 07, 1985
/AP/ /LYPHOMED/ /9MG/ML/ /N88911/001/
/FEB/07,/1985/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
@ FUJISAWA 234MG/ML N19329 001
APR 22, 1987
/@/LYPHOMED/ /234MG/ML/ /N19329/001/
/APR/22,/1987/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
>DLT> /SQUIBB/ /2MCI/VIAL/ /N13993/002/
>ADD> @ SQUIBB 2MCI/VIAL N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
>DLT> /@/CIS/ /50/UCI/ /N17316/001/
>DLT> /100/UCI/ /N17316/002/
>ADD> @ CIS BIOINDUSTRIES 50 UCI N17316 001
>ADD> 100 UCI N17316 002

SOLUTION; ORAL
SODIUM IODIDE I 131
>DLT> /CIS/ /50MCI/ML/ /N17315/001/
>ADD> CIS BIOINDUSTRIES 50MCI/ML N17315 001

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRILIPID 10%
AP MCGAW 10% N19531 001
MAY 28, 1993

NUTRILIPID 20%
AP MCGAW 20% N19531 002
MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AB/ /CHELSEA/ /25MG/ /N87078/001/
B* CHELSEA 25MG N87078 001

>ADD> STRONTIUM CHLORIDE, SR-89

>ADD> INJECTABLE; INJECTION
>ADD> METASTRON
>ADD> MEDI PHYSICS 1MCI/ML N20134 001
>ADD> JUN 18, 1993

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE
/ABBOTT/ /300MG/ /N04125/005/
> DLT > > ADD > @ ABBOTT 300MG N04125 005

SULFAMETHIZOLE

TABLET; ORAL
THIOSULFIL
/WYETH/AYERST/ /250MG/ /N08565/001/
@ WYETH AYERST 250MG N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL
/SANTANOL-DS/
/ROCHE/ /1GM/ /N12715/003/
@ ROCHE 1GM N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
AB BARRE 200MG/5ML;40MG/5ML N72289 001 MAY 23, 1988
AB 200MG/5ML;40MG/5ML N72398 001 MAY 23, 1988
/AB/ /NASKA/ /200MG/5ML;40MG/5ML/ /N72289/001/ /MAY/23,/1988/
/AB/ /200MG/5ML;40MG/5ML/ /N72398/001/ /MAY/23,/1988/ > DLT > > ADD >

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
/AB/ /HEATHER/ /500MG/ /N80189/001/
@ HEATHER 500MG N80189 001

SULFISOXAZOLE ACETYL

/EMULSION;/ORAL/
/LIPO/SANTRISIN/
/ROCHE/ /EQ/1GM/BASE/5ML/ /N09182/009/
@ ROCHE EQ 1GM BASE/5ML N09182 009

SULFISOXAZOLE DIOLAMINE

/OINTMENT;/OPHTHALMIC/
/SANTRISIN/
/ROCHE/ /EQ/4%/BASE/ /N08414/002/
@ ROCHE EQ 4% BASE N08414 002

SULINDAC

TABLET; ORAL
SULINDAC
> ADD > AB MYLAN 150MG N73038 001 JUN 22, 1993
> ADD > AB 200MG N73039 001 JUN 22, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
/+//STUART/ /EQ/10MG/BASE/ /N17970/001/
+ ZENECA EQ 10MG BASE N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
/A-N/STANNOUS/AGGREGATED/ALBUMIN/
/BS/ /NORTH/AM/CHEM/ /N/A/ /N17916/001/
@ NORTH AM CHEM N/A N17916 001

AN-MAA
> DLT > > ADD > /CIS/US/ /N/A/ /N17792/001/
SORIN N/A N17792 001
/TECHNETIUM/TC/99M/MAA/
/BS/ /MEDI/PHYSICS/ /N/A/ /N17773/001/
@ MEDI PHYSICS N/A N17773 001

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
> DLT > /NINTEC/
> DLT > /SQUIBB/ /0.22-2.22CI/GENERATOR/ /N17339/001/
> ADD > @ SQUIBB 0.22-2.22CI/GENERATOR N17339 001

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	DANBURY PHARMA	15MG	N71446 001 MAY 21, 1993
AB		30MG	N71447 001 MAY 21, 1993

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

> DLT >	/AO/	/BEL/MAR/	/25MG/ML/	/N80741/001/
> DLT >	/AO/		/50MG/ML/	/N80742/001/
> DLT >	/AO/		/100MG/ML/	/N80743/001/
> ADD >		ə BEL MAR	25MG/ML	N80741 001
> ADD >		ə	50MG/ML	N80742 001
> ADD >		ə	100MG/ML	N80743 001
> DLT >	/AO/	/STERIS/	/25MG/ML/	/N80188/001/
> DLT >	/AO/		/25MG/ML/	/N85490/001/
> DLT >	/AO/		/100MG/ML/	/N80188/003/
> DLT >	/AO/		/100MG/ML/	/N83595/003/
> ADD >		+ STERIS	25MG/ML	N80188 001
> ADD >		+	100MG/ML	N80188 003
> ADD >			25MG/ML	N85490 001
> ADD >			100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL

SUMYCIN

AB		APOTHECON	50MG	N61147 003
AB			100MG	N61147 002
AB			250MG	N61147 001
AB	+		500MG	N61147 004
/AB/		/SQUIBB/	/50MG/	/N61147/003/
/AB/			/100MG/	/N61147/002/
/AB/			/250MG/	/N61147/001/
/AB//+/			/500MG/	/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

> DLT >	/AP/	/SQUIBB/	/1MCI/ML/	/N18548/001/ /DEC/30,/1982/
> DLT >				
> ADD >		ə SQUIBB	1MCI/ML	N18548 001 DEC 30, 1982
> ADD >				

THEOPHYLLINE

ELIXIR; ORAL

/THEOPHYL-225/ /JOHNSON/RW/		/112.5MG/15ML/	/N86485/001/
ə JOHNSON RW		112.5MG/15ML	N86485 001

THEOPHYLLINE

AA	BARRE	80MG/15ML	N89223 001 MAY 27, 1988
/AA/	/NASKA/	/80MG/15ML/	/N89223/001/ /MAY/27,/1988/

TABLET; ORAL

QUIBRON-T

/+//BRISTOL/MYERS/		/300MG/	/N88656/001/ /AUG/22,/1985/
+ ROBERTS		300MG	N88656 001 AUG 22, 1985
/THEOPHYL-225/ /JOHNSON/RW/		/225MG/	/N84726/001/
ə JOHNSON RW		225MG	N84726 001

/TABLET;/CHEWABLE;/ORAL/

/THEOPHYL/

/JOHNSON/RW/		/100MG/	/N86506/001/ /SEP/12,/1985/
ə JOHNSON RW		100MG	N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL

QUIBRON-T/SR

/BC/	/BRISTOL/MYERS/	/300MG/	/N87563/001/ /JUN/21,/1983/
BC	ROBERTS	300MG	N87563 001 JUN 21, 1983

THEOPHYLLINE SODIUM GLYCINATE

/ELIXIR;/ORAL/

/SYNOPHYLATE/

/CENTRAL/PHARMS/		/EQ/165MG/BASE/15ML/	/N06333/008/
ə CENTRAL PHARMS		EQ 165MG BASE/15ML	N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

>DLT>	AP	BEL MAR	100MG/ML	N80718 001	
>DLT>	AP		200MG/ML	N80712 001	
>ADD>		∂ BEL MAR	100MG/ML	N80718 001	
>ADD>		∂	200MG/ML	N80712 001	
	AP	FUJISAWA	100MG/ML	N80556 001	
	AP	LYPHOMED	100MG/ML	N80556 001	
>DLT>	AP	STERIS	100MG/ML	N80571 002	
>DLT>	AP		200MG/ML	N83534 002	
>ADD>		+ STERIS	100MG/ML	N80571 002	
>ADD>			200MG/ML	N83534 002	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

AB	PAR		10MG	N88351 001	DEC 05, 1983
AB			15MG	N88352 001	DEC 05, 1983
AB			25MG	N88336 001	DEC 05, 1983
AB			50MG	N88322 001	DEC 05, 1983
AB			100MG	N88480 001	DEC 29, 1983
		∂ PAR	10MG	N88351 001	DEC 05, 1983
		∂	15MG	N88352 001	DEC 05, 1983
		∂	25MG	N88336 001	DEC 05, 1983
		∂	50MG	N88322 001	DEC 05, 1983
		∂	100MG	N88480 001	DEC 29, 1983
AB	ZENITH		100MG	N88273 001	OCT 03, 1983
		∂ ZENITH	100MG	N88273 001	OCT 03, 1983

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

+	SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004
+		EQ 30GM BASE/VIAL	N50497 005
			APR 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

+	SYNTEX	250MG	N19979 002 OCT 31, 1991
∂		125MG	N19979 001 MAR 24, 1993

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

>ADD>	AB	NOVOPHARM	5MG	N72648 001 JUN 16, 1993
>ADD>	AB		10MG	N72649 001 JUN 16, 1993
>ADD>	AB		20MG	N72650 001 JUN 16, 1993

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

AB	MYLAN	EQ 400MG BASE	N73393 001 MAY 27, 1993

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

AB	MUTUAL PHARM	50MG	N73136 001 MAR 24, 1993
AB		100MG	N73137 001 MAR 24, 1993

TRETINOIN

SWAB; TOPICAL

RETIN-A

+	JOHNSON RW	0.05%	N16921 002
∂	JOHNSON RW	0.05%	N16921 002

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/0.025%/	/N87990/001/ /JUL/07,/1983/
/AT/		/0.1%/	/N87991/001/ /JUL/07,/1983/
/AT/		/0.5%/	/N87992/001/ /JUL/07,/1983/
	∂ PHARMADERM	0.025%	N87990 001 JUL 07, 1983
	∂	0.1%	N87991 001 JUL 07, 1983
	∂	0.5%	N87992 001 JUL 07, 1983

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	BARRE	0.5%		N89913 001 DEC 23, 1988	> DLT >
/AT/	/NASKA/	/0.5%/		/N89913/001/ /DEC/23,/1988/	> DLT >
/AT/	/PHARMADERM/	/0.025%/		/N88692/001/ /AUG/02,/1984/	> DLT > > ADD >
/AT/		/0.1%/		/N88690/001/ /AUG/02,/1984/	> ADD >
	∂ PHARMADERM	0.025%		N88692 001 AUG 02, 1984	
	∂	0.1%		N88690 001 AUG 02, 1984	

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

/TEP/

/AA/	/GENEVA/	/EQ 10MG BASE/ML/	/N85787/001/ /APR/15,/1982/

TRIFLUOPERAZINE HCL

AA	GENEVA	EQ 10MG BASE/ML	N85787 001 APR 15, 1982

TABLET; ORAL

/TEP/

/AB/	/GENEVA/	/EQ 1MG BASE/	/N85785/001/
/AB/		/EQ 2MG BASE/	/N85786/001/
/AB/		/EQ 5MG BASE/	/N85789/001/
/AB/		/EQ 10MG BASE/	/N85788/001/

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

/SUSPENSION;/ORAL/

/VESPRIN/

/SQUIBB/	/EQ/20MG/HCL/5ML/	/N11491/004/
∂ APOTHECON	EQ 20MG HCL/5ML	N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

/TABLET;/ORAL/

/VESPRIN/

/#/SQUIBB/	/20MG/	/N11123/003/
	/10MG/	/N11123/001/
	/25MG/	/N11123/002/
∂ SQUIBB	10MG	N11123 001
∂	25MG	N11123 002
∂	50MG	N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HCL

AA	NYLOS TRADING	5MG	N85622 001
/AA/	/TABLICAPS/	/5MG/	/N85622/001/

TRIOXSALEN

TABLET; ORAL

TRISORALEN

	/ELDER/	/5MG/	/N12697/001/
> ADD >	ICN	5MG	N12697 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPELENNAMINE HCL

/AA/	/HEATHER/	/50MG/	/N83989/001/
	∂ HEATHER	50MG	N83989 001
AA	NYLOS TRADING	50MG	N85412 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/TABLICAPS/	/50MG/	/N85412/001/	

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

/AP/	/QUAD/	/5MG/ML/	/N89442/001/ /AUG/12,/1988/	
	a QUAD	3MG/ML	N89442 001 AUG 12, 1988	

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

>ADD >	AB	PHARMACAPS	250MG	N73484 001 JUN 29, 1993	
>ADD >					

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER

+	LILLY	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993	

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	MARSAM	2.5MG/ML	N72233 001 FEB 26, 1993	

TABLET; ORAL
VERAPAMIL HCL

>ADD >	AB	WATSON LABS	40MG	N72923 001 JUN 29, 1993
>ADD >				
>ADD >	AB		40MG	N72924 001 JUN 29, 1993
>ADD >				

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE

	FUJISAWA	1MG/ML	N89515 001 APR 29, 1987
	/LYPHOMED/	/1MG/ML/	/N89515/001/ /APR/29,/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL
AFAXIN

	a STERLING	EQ 50,000 UNITS BASE	N83187 001

VITAMIN A

/AA/	/WHARTON/	/EQ 50,000 UNITS BASE/	/N83665/001/
	a WHARTON	EQ 50,000 UNITS BASE	N83665 001
/AA/	/ZENITH/	/EQ 50,000 UNITS BASE/	/N83035/001/
/AA/		/EQ 50,000 UNITS BASE/	/N83190/001/
	a ZENITH	EQ 50,000 UNITS BASE	N83035 001
	a	EQ 50,000 UNITS BASE	N83190 001

INJECTABLE; INJECTION
AQUASOL A

>DLT >/AP/	/ASTRA/	/EQ 50,000 UNITS BASE/ML/	/N06823/001/
>ADD >	ASTRA	EQ 50,000 UNITS BASE/ML	N06823 001
>DLT >	/VITAMIN A PALMITATE/		
>DLT >/AP/	/BEL/MAR/	/EQ 50,000 UNITS BASE/ML/	/N80819/001/
>ADD >	a BEL MAR	EQ 50,000 UNITS BASE/ML	N80819 001

XENON, XE-133

GAS; INHALATION
XENON XE 133

AA	MEDI PHYSICS	10MCI/VIAL	N17687 002
AA		20MCI/VIAL	N17687 003

XYLOSE

POWDER; ORAL
XYLO-PFAN

/AA/	/ADRIA/	/25GM/BOT/	/N17605/001/
AA	SAVAGE	25GM/BOT	N17605 001

ZINC SULFATE

>_DLT_>	/INJECTABLE;/INJECTION/		
>_DLT_>	/ZINC/SULFATE/		
>_DLT_>	/LYPHOMED/	/EQ/1MG/ZINC/ML/	/N19229/002/
>_DLT_>			/MAY/05,/1987/
>_ADD_>	@ LYPHOMED	EQ 1MG ZINC/ML	N19229 002
>_ADD_>			MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL
NEOPAP
>_DLT_> /ALCON/ /120MG/ /N16401/001/
>_ADD_> POLYMEDICA 120MG N16401 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ISOCLOR
CIBA 8MG;120MG N18747 001
MAR 06, 1986
/FISONS/ /8MG;120MG/ /N18747/001/
/MAR/06,/1986/

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK
+ SCHERING PLOUGH 1%;100MG N20289 002
APR 26, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
BARRE 12.5MG/5ML N70497 001
APR 25, 1989
/NASKA/ /12.5MG/5ML/ /N70497/001/
/APR/25,/1989/

IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEM/ /200MG/ /N72901/001/
/DEC/19,/1991/
/200MG/ /N72903/001/
/DEC/19,/1991/
IBUPROFEN
NORTON HN 200MG N71144 001
JAN 20, 1987
200MG N72901 001
DEC 19, 1991
200MG N72903 001
DEC 19, 1991

IBUPROFEN

TABLET; ORAL
/IBUPROFEN/
/OHM/ /200MG/ /N71214/001/
/DEC/01,/1986/

IBUPROFEN
/ZENITH/ /200MG/ /N71154/001/
/OCT/27,/1987/
@ ZENITH 200MG N71154 001
OCT 27, 1987
IBUPROHM
OHM 200MG N71214 001
DEC 01, 1986
/NEUVIL/
/LUCHEM/ /200MG/ /N71144/001/
/JAN/20,/1987/

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
WATSON LABS 1MG/5ML N73062 001
MAY 28, 1993

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 7 COMBINATION PACK
+ ADVANCED CARE 2%;100MG N20288 002
APR 26, 1993

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N19208/001/
/JAN/15,/1985/

/SYRUP;ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /30MG/5ML;1.25MG/5ML/ /N11935/003/
/NOV/26,/1982/
/TRIOFED/
/BARRE/ /30MG/5ML;1.25MG/5ML/ /N88115/001/
/MAR/04,/1983/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/SYRUP;/ORAL/
/TRIPOSED/
/HALSEY/ /30MG/5ML;1.25MG/5ML/ /N88213/002/
/MAR/30;/1984/

/TABLET;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N11936/002/
/NOV/26;/1982/
/TRI-SUDO/
/MD/PHARM/ /60MG;2.5MG/ /N85024/002/
/JAN/16;/1984/
/TRIPODRINE/
/DANBURY/PHARMA/ /60MG;2.5MG/ /N88112/001/
/JAN/20;/1983/
/TRIPOSED/
/HALSEY/ /60MG;2.5MG/ /N88192/002/
/MAY/01;/1984/
/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/
/CHELSEA/ /60MG;2.5MG/ /N88118/002/
/JAN/26;/1984/

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 6 / JUNE '93

INDIUM^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM N/A N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru June 1993]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
8-METHOXSALEN TN= UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
AMINOSALICYLATE SODIUM TN=	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF TUBERCULOSIS.	UNIVERSITY OF ILLINOIS AT CHICAGO 833 SOUTH WOOD STREET M/C 886 ROOM 176 CHICAGO IL 60612 DD 05/14/93 MA / /
ANTI-THYMOCYTE SERUM TN= NASHVILLE RABBIT ANTI-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
APOMORPHINE HCL INJECTION TN=	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
ATOVAQUONE TN= MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
ATOVAQUONE TN= MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	KIM, SINIL M.D. UCSD CANCER CENTER/0812 SAN DIEGO CA 92103 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT,INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
MODAFINIL	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
NITRIC OXIDE TN=	TREATMENT OF PRIMARY PULMONARY HYPERTENSION IN THE NEWBORN.	ANAQUEST, INCORPORATED 110 ALLEN ROAD LIBERTY CORNER NJ 07938 DD 06/22/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOOR NEW YORK NY 10022 DD 04/22/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
RILUZOLE TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
SOMATROPIN TN= BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /

NAME *Generic/Chemical* *TN=Trade Name*	*INDICATION DESIGNATED*	*SPONSOR & ADDRESS* *DD=Date Designated* *MA=Marketing Approval*
THALIDOMIDE TN=	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
TRETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN 1 TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

BUMETANIDE (TABLET)	APR 23, 1993
CEFACLOR (CAPSULE AND SUSPENSION)	APR 23, 1993
CAPTOPRIL (TABLET)	MAY 13, 1993
GLIPIZIDE (TABLET)	APR 23, 1993
GLYBURIDE (TABLET)	APR 23, 1993
GUANABENZ ACETATE (TABLET)	APR 23, 1993
INDAPAMIDE (TABLET)	APR 23, 1993
KETOPROFEN (CAPSULE)	APR 23, 1993
PINDOLOL (TABLET)	APR 23, 1993
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993
TRIAZOLAM (TABLET)	DEC 24, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.					
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.					
AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-20	SINGLE 32MG DOSE

REFERENCES
NEW INDICATION

I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE

REFERENCES
PATENT USE CODE

U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19604 001	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005			
	19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005		NS	DEC 23, 1995
	19402 001	ASTEMIZOLE; HISMANAL	4219559	AUG 26, 1999		NCE	DEC 29, 1993
	20045 001	AVOBENZONE; SHADE UVAGUARD	4522807	JUN 11, 2002		NC	DEC 07, 1995
			4387089	JUN 07, 2002			
	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	20186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
	20186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
	20186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
						NC	FEB 26, 1996
	20229 001	CLADRIBINE; LEUSTATIN				NCE	FEB 26, 1998
						ODE	FEB 26, 2000
>ADD>	19287 001	DIAZEPAM; DIZAC				NDF	JUN 18, 1996
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	18651 001	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 002	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 003	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	19616 004	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001	ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998
	20073 001	FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001			
			4194009	APR 19, 1994			
			4018895	APR 19, 1994	U-12		
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
	20123 001	GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
	17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19726 001	GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
>ADD>	20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	JUL 06, 1993
>ADD>	20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
>ADD>						NCE	DEC 30, 1996
	19084 001	KETOCONAZOLE; NIZORAL				NS	JUN 30, 1996
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4335125	JUN 15, 1999		I-30	JAN 27, 1996
			5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
			4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
	20263 001	LEUPROLIDE ACETATE; LUPRON	4089969	MAY 16, 1997	U-75		
			4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
			4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
			4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
			4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			4652441	MAR 24, 2004			
	18948 001	LEVOCARNITINE; CARNITOR	4005063	JAN 25, 1996		ODE	APR 16, 2000
>ADD>						I-86	DEC 16, 1995
	18948 002	LEVOCARNITINE; CARNITOR				ODE	DEC 16, 1999
>ADD>						I-86	DEC 16, 1995
>ADD>	19558 001	LISINOPRIL; PRINIVIL				ODE	DEC 16, 1999
>ADD>	19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
	20049 001	MESALAMINE; PENTASA				NP	MAY 10, 1996
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
	20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	FEB 01, 1997	U-53		
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
>ADD>	19795 001	PODOFILOX; CONDYLOX				NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN				I-90	MAR 08, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	50689 001	RIFABUTIN; MYCOBUTIN					
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT				ODE	DEC 23, 1999
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19766 001	SIMVASTATIN; ZOCOR	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
>ADD>	20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19050 001	SUFENTANIL CITRATE; SUFENTA				NCE	JUN 18, 1998
						NR	MAR 19, 1996
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX				I-89	MAR 19, 1996
	19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3	4816470	MAR 28, 2006	U-72		
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX				I-87	NOV 27, 1995
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	18163 003	TEMAZEPAM; RESTORIL	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
>ADD>	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
			4591592	NOV 01, 2005			
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4051141	SEP 27, 1996		NCE	OCT 31, 1996
			4591592	NOV 01, 2005			
	18776 003	VECURONIUM BROMIDE; NORCURON	4051141	SEP 27, 1996		NCE	OCT 31, 1996
			4297351	OCT 27, 1998			
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4237126	DEC 02, 1997		NCE	APR 30, 1994
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
			4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19862 001	INDIUM 111 CHLORIDE; INDICLOR				NCE	DEC 29, 1997

*U.S. Government Printing Office: 1993 — 342-345/60013

New 13th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7023

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (04/93)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 783-3238.